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ABSTRACT 
The availability of complete sequences for the genomes of many organisms changes the    
researcher’s attention from genome sequencing to finding the function of gene products, the 
proteins. The three dimensional (3D) structure of a protein is helpful to understand its function, 
because tertiary structure is more conserved in evolution than sequence.  The 3D structures can 
be found quickly by using high-throughput (HT) methods for protein expression, purification, 
characterization and structure determination. This process is very challenging in every step. 
Therefore we selected nearly 200 cancer related proteins as targets to see the difficulties in trying 
to determine the web predicted structural properties that make the protein easy to produce and 
crystallize using current technologies. Selection of targets, gene carriers or vectors and the 
expression strains of Escherichia coli K12-MG1655 (EC) are very important to obtain soluble 
expression clones and pure protein for crystallization and structure determination. 
Identification of protein function based on 3D structural analysis comes after the structure 
determination. We described a new calculation method called frame method to characterize the 
proteins in the mu-crystallin fold family. Two functionally characterized proteins, ornithine 
cyclodeaminase (OCD) and alanine dehydrogenase (AlaDH), are used as frames in order to 
annotate the activity of OCD like 1 from thermophilic Sulfolobus solfataricus P2 (Ss) and the 
human mu-crystallin enzyme.  OCD like 1 seems to have OCD activity, but the human enzyme 
does not, as described in the literature. In the meantime, OCD like 1 expression was tested and 
purified to test for OCD activity to validate our calculations. We were not able to purify OCD 
like 1; therefore the determination of catalytic activity of it will require future studies.  
 
 iv
Crystallization, structure determination and identification of protein function are 
dependent on each other; therefore we started crystallization studies of Phosphoinositide-specific 
phospholipase C (PI-PLC) from Streptomyces antibioticus (Sa) to better understand the 
mechanism of action of the PLC protein family. SaPLC is purified by affinity, gel filtration and 
ion exchange chromatographies. SaPLC crystals are obtained using the hanging drop 
crystallization technique at concentrations of 20-24 % polyethylene glycol (PEG) 17500 and 1.5-
2 % 1,4- dioxane for 35-40 mg/mL protein.  The main major barrier to success of structure 
determination is the preparation of well-diffracting crystals for X-ray diffraction studies, which 
we are currently optimizing. 
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CHAPTER ONE: INTRODUCTION 
1.1. Medium scale project of cancer related proteins 
Genomic research makes it possible to look at biological phenomena on a very large scale such 
that all genes in a genome and the three dimensional (3D) structures of the proteome encoded by 
a given genome can be understood. Structural genomics (SG) or structural proteomics will define 
the protein structure-function relationships. Unfortunately, even when a genome can be 
sequenced, only part of it can be exogenously expressed as soluble proteins. Furthermore, only a 
fraction of the soluble proteins produce crystals, at least at the present state of technology. 
Consequently, actual SG projects are in fact targeted projects, and they address medical issues in 
fields such as oncology, neurological, and infectious diseases that monogenic approaches failed 
to solve because the underlying molecular mechanism implicated more than one gene [1]. 
Reproducible and cost efficient high-throughput (HT) methods can be used for collecting very 
large scale of protein folds or protein function information. In the HT projects, to get data in a 
little time, a target is rejected if it does not respond to the first set of expression conditions, but in 
a medium scale project a target is going to be tested under different experimental conditions, 
after the evaluation of expression experiments.  
We initiated a medium scale cancer related protein project by studying bioinformatics and 
proteomics of novel cancer enzymes that are found from the National Center for Biotechnology 
Information (NCBI). After browsing human and mouse genomes, nearly 200 cancer proteins 
were considered structural genomics targets for our study because their structure identity to any 
known structure in Protein Data Bank (PDB) is less than 50% [1].The use of homologous 
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proteins from different organisms (e.g. Bacterium) improves the chances of success in cloning 
steps, because mammalian genes are hard to amplify and good expression of soluble and folded 
proteins[2]. Another advantage of using homologues of mammalian proteins is that bacterial 
proteins are easier to express in EC [3]. If the structure of the homolog proteins can be 
understood, these structures will use to generate structural models for other unknown cancer 
proteins in humans. 
The rate determining step in any structural proteomics project is the generation of quality protein 
samples [4].The project was started to understand the difficulties observed during the process. 
The goal of this project is not finding the 3D structures of all target proteins, but rather finding 
the important features of these proteins such as pI, grand average of hydropathicity (GRAVY), 
molecular weight, secondary structure ,etc., that allow them to be produced and purified to 
produce X-ray quality crystals. 
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1.2. Structural study of Ornithine Cyclodeaminase (OCD)  
 
 The mu-crystallin protein family has many homologs in all three kingdoms. Among 
archeabacteria, no functions besides alanine dehydrogenase are known, although the sequence 
variation is relatively high. In some eubacteria, the homolog is known to function as ornithine 
cyclodeaminase (OCD). In diurnal marsupials (for example kangaroo), the protein homolog 
serves as a major component of eye lens and gives the entire family its name. In man, nearly 
identical proteins appear to have another function, involving thyroxin binding. The function in 
plants is unknown. While it is convenient to consider the protein family in terms of these major 
taxonomic groups, the sequences do not group so neatly, and some archeal and bacterial 
sequences appear to be more similar to the mammalian than to other members of their own 
kingdom. In general, all the homologs share about 30% identity, and both biochemical evidence 
and sequence analysis indicate that nicotinamide adenine dinucleotide (phosphate) NAD(P) 
binding is conserved [5]. Due to the strong sequence conservation across this family, structures 
of alanine dehydrogenase from Archaeoglobus fulgidus (1OMO) and ornithine cyclodeaminase 
from Pseudomanas putida (1X7D) provide an approximate model for other members of mu-
crystallin family. The purpose of this study is to understand the mechanism of action of this 
family. To do that, active sites of OCD like 1 from Sulfolobus solfataricus and human mu- 
crystallin and their catalyzed reactions are investigated. OCD like 1 and OCD like 2 from 
Sulfolobus solfataricus enzymes were expressed, purified and tested for enzymatic activity in 
order to validate the computational data. 
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Alanine dehydrogenase (AlaDH, EC 1.4.1.1) catalyzes the NADH-dependent reversible 
amination of pyruvate to L-alanine. The catalytic mechanism of this reaction is shown in the 
Figure 1. 
H
NH2
CH3-O
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O NH2+
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Figure 1. Mechanism of alanine dehydrogenase. 
 
This figure proposes that the alanine (Substrate 1) carboxylate group is bound by an arginine or 
lysine side chain and the first step of the reaction in the direction of oxidative deamination 
involves hydride transfer between the C alpha of alanine and the C4 of the nicotinamide ring, to 
produce a protonated iminopuyruvate (Substrate 2). A conformational change occurs that allows 
a water molecule to enter the active site attacking the iminopyruvate to produce a carbinolamine 
(Substrate 3) in a process thought to be facilitated by H bonding of water to a cationic acid 
(probably histidine), which increases its nucleophilicity. Finally, the collapse of the 
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carbinolamine yields pyruvate (Substrate 4) and ammonia [6]. Ornithine cyclodeaminase (OCD) 
catalyzes the conversion of L-ornithine to L-proline by an NAD dependent hydride transfer 
reaction that culminates in ammonia elimination. Figure 2 summarizes the catalytic mechanism 
of this reaction.  
O-
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H
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+H3N
O-
O
NH2+
+H3N
NH2+
O-
O+H3N
NAD+
B:
Asp 228-COO-
NADH
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Asp 228-COOH
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O-
O
NAD+
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B:
Substrate 1 Substrate 2
Substrate 3
Substrate 4
Substrate 5
 
Figure 2. Mechanism of ornithine cyclodeaminase. 
 
L-ornithine (Substrate 1) binds to the active site, and hydride transfer to the re face of NAD+ 
occurs, resulting in imino substituent (Substrate 2). This process is facilitated by transfer of H+ 
to the side chain of aspartate 228. Next, the sigma amino group directly attacks the C2 position 
of L-ornithine (Substrate 3) in a manner that brings it close to the side chain of glutamic acid 56. 
Elimination of ammonia results in an electrophilic C2 center (Substrate 4) that is susceptible to 
hydride transfer from NADH, yielding the L-proline product (Substrate 5) [7]. 
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1.3. Crystallization of saPLC  
 
A diverse array of second messengers is generated by breakdown of membrane phospholipids. 
Binding certain hormones and growth factors to their respective receptors triggers a sequence of 
events that can lead the activation of specific phospholipases [8].  Phosphatidylinositol-specific 
phospholipases C (PI-PLC) play a central role in signal transduction cascades, hydrolyzing 
inositol phospholipids (PIP) to two important second messengers, inositol trisphosphate (IP3) and 
diacylgylcerol (DAG).  These enzymes also generate the cylic inositol phosphate, as a result of a 
premature escape of the intermediate from the active site. The Ca2+-dependent mammalian PI-
PLC usually produces a mixture of 1,2-cyclic phosphate (IcP 2) and inositol 1-phosphate (IP 3); 
bacterial PI-PLC usually produces exclusively IcP 2. However, formation of both IcP and IP by 
Bacillus cereus PI-PLC has been reported [9]. 
The proposed mechanism of PI-PLCs is summarized in Figure 3. The binding of the ligand to a 
cell surface receptor, R, actives a phosphoinositide-specific phospholipase C through the 
intermediacy of a G protein. Phospholipase C catalyzes the hyrolysis of PIP2 to IP3 and DAG. 
The water-soluble IP3 stimulates the release of Ca++ sequestered in the endoplasmic reticulum, 
which, in turn, activates numerous cellular processes through the intermediacy of calmodulin and 
its homologs. The nonpolar DAG remains associated with the inner leaflet of the membrane, 
where it is activates protein kinase C to phosphorylate, and thereby modulates the activities of a 
number of cellular proteins [10]. 
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Figure 3. The proposed mechanism of PI-PLCs. 
 
The catalytic activity of mammalian PI-PLCs is strictly dependent on calcium as a cofactor and 
increases with a rise of calcium concentration within the physiological range [11]. Due to 
difficulties of working with mammalian enzymes, the bacterial PI-PLCs can be used as a model 
system for kinetic and structural investigations.  But the smaller and less complex bacterial 
enzymes utilize a guanidinium group provided by an active site arginine residue. They do not 
need calcium as a cofactor. We chose SaPLC from Streptomyces antibioticus (Sa) a candidate to 
crystallization study because it is a PLC that is dependent on calcium to be catalytically active. 
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Structure determination of SaPLC depends on finding suitable crystallization conditions. In order 
to obtain a crystal, the protein molecules must assemble into a periodic lattice. One starts with a 
solution of the protein with a fairly high concentration (2-50 mg/mL) and adds reagents that 
reduce the solubility close to spontaneous precipitation. By further concentration, and under 
conditions suitable for the formation of a few nucleation sites, small crystals start to grow. Often 
very many conditions have to be tried to succeed. This is usually done by initial screening, 
followed by a systematic optimization of conditions [12]. Crystals should to be a few tenths of a 
mm in each direction to be useful for diffraction experiments, and then they are mounted in a 
capillary tube and placed in an X-ray beam from either a laboratory or a synchrotron source.  The 
diffraction pattern is collected and analyzed to obtain the structure of the protein [13]. 
The most common setup to grow protein crystals is by the hanging drop technique: a few 
microliters of protein solution are mixed with an about equal amount of reservoir solution 
containing the precipitants. A drop of this mixture is put on a glass slide which covers the 
reservoir. As the protein/precipitant mixture in the drop is less concentrated than the reservoir 
solution, water evaporates from the drop into the reservoir. As a result the concentration of both 
protein and precipitant in the drop slowly increases, and crystals may form. There is a variety of 
other techniques available such as sitting drops, dialysis buttons, and gel and microbatch 
techniques. Robots are useful for automatic screening and optimization of crystallization 
conditions [12]. 
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CHAPTER TWO: EXPERIMENTAL DETAILS 
2.1. Chemicals and Materials 
All chemicals and solutions used were from Sigma (USA) or Fisher Scientific (USA), unless 
stated otherwise in the text. Nucleotides (dNTP’s) were purchased from Eppendorf (USA), 
template Deoxyribonucleic acid (DNA) was obtained from ATCC (USA) or Ohio State 
University. Cloned or Turbo Pfu Polymerase from Stratagene (USA), T33 from Ohio State 
University, primers  from IDTDNA (USA), restriction endonuclease enzymes and Calf Intestinal 
Alkaline Phosphatase (CIP), T4 ligase, T4 Polynucleotide kinase from New England Biolabs Inc 
(USA). 
All buffer recipes and settings for the equipments can be found in Appendix A. 
2.2. Amplification of target genes 
Polymerase chain reaction (PCR) is a very powerful tool for DNA amplification.  
Many types of PCR methods can be found. Touch –down PCR is used to reduce non-specific 
PCR product by decreasing annealing temperature in steps. Two different procedures were 
followed by using Taq DNA polymerase (T33) and Turbo Pfu polymerase. When T33 enzyme 
was used, exact amount of  ingredients were mixed together in order to get final concentrations 
of 1X PCR buffer, 1 mM dNTP’s, 1 ng/µl template DNA,  and 0.2 µM of each primers (5’ and 3’ 
primers) and optimum MgCl2 concentrations for maximum enzyme activity. Some additives like 
betaine monohydrate and dimethylsulfoxide (DMSO) or both of them together were added to the 
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PCR mixture to be able to amplify some target genes. 5’ primers were treated with T4 
polynucleotide kinase in order to add 5’-phosphates to oligonucleotides to allow subsequent 
ligation [14]. The Turbo Pfu DNA polymerase instruction manual was followed when Turbo Pfu 
DNA polymerase was used [15]. After PCR, amplified genes were visualized on the agarose gel.  
2.3. Pouring, running and visual analysis of Agarose gels 
Analytical agarose gels allow separation and identification of nucleic acids based on size and 
charge migration. The concentration of agarose used for the gel depends primarily on the size of 
the DNA fragments to be analyzed. 1 % (w/v) was used for separating 0.5-10 kb DNA 
fragments. 1x TAE running buffer was prepared both to pour the gel and fill the electrophoresis 
tank. Appropriate amounts of agarose were added to an appropriate volume of 1X TAE running 
buffer in a flask. The slurry was heated in a microwave by swirling the vessel occasionally, until 
the agarose was dissolved. Agarose was cooled to 55-60 ˚C. Ethidium bromide was added and 
agarose solution was poured onto the gel tray after inserting the comb. Then, the gel was left to 
set for 30 min. The comb was carefully removed from the gel and tank is filled with 1X TAE 
running buffer. Then ethidium bromide was added to the tank. DNA samples that were mixed 
with gel loading buffer were loaded to the wells of the gel. The electrodes were connected to 
Agarose gel VWR 105 electrophoresis power supply (VWR Scientific E-C Apparatus 
Corporation, USA) so that DNA will migrate towards to the anode and power supply was turned 
on and the gel was run at 100-125  mV until the dye have migrated to the bottom of the gel. 
Finally, the gel was visualized with an Alpha Imager TM 2200 Multilmage TM Light Cabinet 
Alpha Innotech Corparation (Alpha Innotech Corporation, USA). 
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2.4. PCR purification 
QIAquick PCR purification kit from Qiagen Inc. (USA) was used to purify single or double 
stranded DNA fragments from PCR and other enzymatic reactions. Fragments ranging from 100 
bp to 10 kb were purified from primers, nucleotides, polymerases, and salts using QIAquick spin 
columns in a micro centrifuge. Five volumes of Buffer PB (Binding buffer) to 1 volume of the 
PCR sample were added and mixed. QIAquick spin column was placed in a provided 2 mL 
collection tube. The sample was applied to the QIAquick column to bind DNA and was 
centrifuged at 13200 rpm for 30–60 s by using Eppendorf 5415D (Brinkmann Instruments, 
USA). The flow-through was discarded and the QIAquick column was placed back into the same 
tube. Buffer PE (washing buffer, 0.75 mL) was added to the QIAquick column as a washing step 
and tube was centrifuged for 30–60 s. Flow-through was discarded again and the tube was spun 
down for an additional 1 min. The QIAquick column was placed in a clean 1.5 mL micro 
centrifuge tube. For increased DNA concentration, 30 µl elution buffer EB was added to the 
center of the QIAquick membrane, the column was let stand for 1 min, and then centrifuged [16]. 
Purified DNA fragments have no origin of replication, the site where DNA replication begins, so 
they can not replicate themselves and produce proteins. Therefore, they require carriers called 
vectors. Vectors have origin of replication site and DNA fragments can be placed in them. pET-
28a from Novagen (USA) and pQE-30 UA vectors Qiagen Inc. (USA) were used as DNA 
carriers.  
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2.5. Preparation of pET-28a vector 
2.5.1. Double digestion of pET-28a vector 
Restriction endonuclease enzymes recognize specific sequences in DNA molecules and make 
cuts in both strands. Some restriction endonucleases cut in the middle of their recognition site, 
creating blunt-ended DNA fragments. However, the majority of the enzymes make cuts 
staggered on each strand, resulting in a few base pairs of single-stranded DNA at each end of the 
fragment, known as sticky ends. pET-28a vector has BamHI, NdeI, NheI and XhoI cutting sites 
that form sticky end DNA (Figure 4) [17]. 
BamHI – NdeI, or  XhoI 
The vector was digested with BamHI restriction enzyme in BamHI buffer at 37° C for 2 h, then 
enzyme was inactivated at 65 °C for 20 min to prevent cutting activity of second enzyme. NdeI, 
XhoI restriction enzymes were added and the mixture was incubated at 37 °C for 2 h. 
BamHI – Nhe I  
Vector was digested with BamHI restriction enzyme in BamHI buffer at 37° C for 2 h, then 
enzyme was inactivated at 65 °C for 20 min. The vector was cleaned to remove extra enzyme 
and buffer using a QIAquick PCR purification kit (procedure was same as PCR purification). At 
the end, the Nhe I restriction enzyme and NE buffer 2 were added and the mixture was incubated 
at 37 °C for 2 h [14]. 
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Figure 4. pET-28a (+) vector map. 
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2.5.2. Calf Intestinal Alkaline Phosphatase (CIP) treatment of pET-28a vector after double 
digestion  
CIP treatment was necessary to stop self ligation of pET-28a vector. Enzymes were inactivated 
at 65 °C for 20 min,  vector and buffers mixture were treated by CIP and incubated at 37° C for 2 
h, CIP was inactivated like other enzymes and  vector was purified by using QIAquick PCR 
Purification Kit and stored at -20 °C [14]. 
2.6.Preparation of target gene inserts 
The protocol for double digestion of pET-28a vector was followed to prepare inserts. CIP 
treatment after digestion of inserts was not necessary, they were just cleaned by using QIAquick 
PCR Purification Kit and then stored at -20 °C. Inserts and vectors that were cut by different 
restriction nucleases were quantified at the wavelength of 260 nm by using Lambda 25 UV/ Vis 
Spectrometer (Perkin Elmer Instruments, USA) and their concentrations were calculated by 
using the following formula [18]. 
Concentration = OD260 x 50 µg/ mL x dilution factor  
2.7. Ligation with pET-28a vector 
Prepared pET-28a vector (50 ng/μl) and prepared target gene insert (0.2 pmol = 50 ng of a 500bp 
fragment) and sterile water were incubated at 65 °C for 5 min and  at room temperature for 5 min 
in order to join vector and insert efficiently. Then, 10X T4 ligase buffer and 1 μl T4 ligase 
ezyme were added and ligation mixture was incubated at 16 °C overnight. This can be stored at -
20 °C for future use [19]. 
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2.8. Ligation with pQE-30 UA vector 
PCR products generated using T33, which does not have proofreading activity, have a 3’end A, 
so using pQE-30 UA vector (Figure 5) increases the ligation efficiency. The manufacturer 
recommends using a 5-10 fold molar excess PCR product DNA over PQE-30 UA vector DNA 
for better ligation and transformation. pQE-30 UA vector, PCR products and sterile water were 
incubated at 65 °C for 5 min and in ice for 5 min in order to join vector and insert efficiently. 
Then, 10x T4 ligase buffer and 1 μl T4 ligase ezyme were added and ligation mixture was 
incubated at 16 °C overnight. It was stored at -20 °C for future use [19]. 
 
Figure 5. pQE-30 UA vector for direct cloning of PCR products into an expression vector  
PT5: T5 promoter, lac O: lac operator, RBS: ribosome binding site, ATG: start codon, 6xHis: 
His tag sequence, MCSI/MCSII: multiple cloning sites, Stop Codons: stop codons in all three 
reading frames, Col E1: Col E1 origin of replication, Ampicillin: ampicillin resistance gene. 
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2.9. First transformation 
Cells that have the ability to take up DNA from a variety of sources are termed competent cells. 
Before transformation of DNA into them, they were made according to the following procedure. 
The cell lines used were Nova Blue singles, Nova Blue TIR from Novagen (USA).  
2.9.1. Preparation of Competent Cells 
Everything needs to be sterile throughout the entire process. An LB/Agar plate was streaked with 
competent Escherichia coli cells and grew at 37 °C for overnight (16-20 h). One colony from the 
plate was inoculated into 2 mL of 2xTY or Luria-Bertani (LB) media and was placed in shaker 
overnight.  1 mL of the cell growth was pipetted into Erlenmeyer flask that contains autoclaved 
100 mL of 2xTY or LB media, and then each Erlenmeyer flask was placed in shaker at 37 °C 
250 rpm for 3-4 h. Absorbance was read periodically over the 3-4 h at 600 nm by using Lambda 
25 UV/ Vis Spectrometer (Perkin Elmer Instruments, USA) to get optical density between 0.7 
and 0.8. When the absorbance was got in range, the cells were poured into 50 mL ice cold 
conical tubes and centrifuged at 4 °C and 3000 rpm for 10 min by AvantiTM J-20 XP centrifuge 
(Beckman Coulter, USA). Excess cell solution was decanted and the cell pellet was resuspended 
in 50 mL of ice cold 0.1 M CaCl2. The tubes were gently swirled for several min to disperse the 
pellet into the CaCl2 and then they let stand on ice for 30 min. Cells were centrifuged again at 
4°C and 3000 rpm for 10 min. Pellet was re-suspended in 5 mL of 0.1 M CaCl2 and was 
dispersed into the solution by gently shaking to tubes for several min. Competent cells were 
stored at 4 °C for 3-4 d, because they give higher transformation rates [20]. 
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2.10. Methods for transformation 
Two methods were used to transform plasmid DNA to competent cells.  
2.10.1. Heat shock transformation method 
If the competent cells that were made according to above procedure, first step was pipetting 100 
μL of competent cells into 15 mL Falcon tubes. Then, plasmid DNA was added to the tubes and 
tubes were cooled on ice for 30 min. Tubes were heat shocked at 42 °C for 30 s to make sure 
plasmid pass through cell membrane and was taken inside the cell; tubes were placed back in the 
ice for 5 min. The cells were pipetted into a 10 mL Fisher tube with 500 μL of 2xTYor LB 
media. The fisher tube with the cells was placed into the G24 environmental Incubator Shaker 
(New Brunswick Scientific Co. Inc, USA) at 37 °C for 45-60 min. 200 μL of the cells was plated 
onto pre-warmed plates of choice using a glass rod. Positive control (cells with test plasmid on 
the plate) and negative control plates (cells only without plasmid DNA and with nothing on the 
plate) were also included in the sample plates. All plates of cells and controls were placed in a 
TS Auto Flow CO2 water-jacketed incubator (USA) at 37 °C overnight. Results were checked 
the next day and colonies that were growing on the plates were counted to obtain yield. [20] 
If Nova Blue competent cells from Novagen (USA) were used for heat shock transformation 
method, similar procedure has to be followed. Differences were the volume of competent cells 
that were needed and volume of plating cells. Because competent cells from Novagen were much 
more efficient and give higher transformation yield, the amount of used and plated cells were 
less, 20 μL and 50 μL, respectively. Centrifugation of plating cells with an Eppendorf 5415D 
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(Brinkmann Instruments, USA) at 13200 rpm for 1 minute was sometimes necessary to get 
higher transformation yields.  
2.10.2. Electroporation method 
Competent cell preparation  
One liter of culture was pelletted at 4000 x g at 4˚C for 15 min by using AvantiTM J-20 XP  
centrifuge (Beckman Coulter, USA ). Pellet was re-suspended one volume sterile cold H2O.  
Centrifugation and re-suspension of pellet was continued several times until adding 0.002-0.003 
volume cold sterile H2O to the pellet, then competent cells were ready to use. 
Electroporation  Procedure 
Volume of competent cell was 40 μL and 1 μL plasmid was mixed with cells in electroporation 
cuvette. Automatic charge was activated and cells were pulsed approximately 5-6 ms, 960 μL LB 
or SOC media was added into the cuvette immediately after pulse. Cells were transferred to 
polypropylene tube and held at 37 ˚C for 45 min. 1-100 μL of cells were transferred to an 
appropriate agar plate containing antibiotic. Next day, results were recorded [21]. 
2.11. Screening the transformant 
2.11.1. Digestion Screening  
Liquid cultures of transformants were grown overnight, plasmid DNA was isolated by using 
QIAprep Spin Miniprep Kit. QIAprep Spin Miniprep Kit was designed for purification of up to 
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20 µg of high copy DNA plasmid from 1-5 mL overnight cultures of EC in LB medium. 
Bacterial cells were pelleted at 4000 x g at 4˚C for 10 min by using AvantiTM J-20 XP centrifuge 
(Beckman Coulter, USA). The pellet was re-suspended in 250 µl of Buffer P1 and transferred to 
a new micro centrifuge tube. 250 µl of Buffer P2 was added and the tube was inverted 4-6 times 
to mix. 350 µl of Buffer N3 was added and tube was mixed by inverting, then cleared bacterial 
lysate was centrifuged by an Eppendorf 5415D (Brinkmann Instruments, USA) at 13000 rpm for 
10 min. Supernatant was applied to the QIAprep spin column (a silica column) and plasmid 
DNA was bound to it after the centrifugation for 1 minute. Column was washed with 0.5 mL of 
Buffer PB and 0.75 mL of Buffer PE and wash buffers were discarded after three 1 minute 
centrifugations. 50 µl of Buffer EB was applied to the column to elute plasmid DNA [22]. 
Plasmid DNA was digested with the suitable restriction enzymes and an agarose gel was run to 
see the positively verified inserts. 
2.11.2. Directional PCR methods 
This method was followed if a gene was ligated with the pQE-30 UA vector. Colonies from a 
plate were picked and grown in 100 µL of LB and antibiotic for 3 h. 5 µL of this growth was 
added to 95 µL of water and boiled at 95 °C for 10 min. The remaining culture was mixed with 
50 µL of 50 % glycerol, and samples were stored at -80 °C in order to be used for further 
experiments. 2 µL of the boiled culture was used in a 50 µL PCR mixture that contains 1X PCR 
buffer, 0.2 mM dNTP’s, 1.7 M betaine monohydrate, 1.5 mM MgCl2, 0.25 µM vector specific 
primer and gene specific primer. In the modified version of this procedure, 2 µL plasmid DNA 
was added to PCR mixture instead of boiled culture. This was a time saving but a more 
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expensive procedure.  Finally, PCR products were run on the agarose gel and the colonies that 
have the right size insert were determined.  
2.12. Second transformation for protein expression 
Rosetta (DE3) placI, BL21(DE3) from Novagen (USA) and  DL41 were used for the second 
transformation to make protein expression possible. This was due to these strains containing 
isopropyl-beta-D-thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase. The procedure 
was same as first transformation; glycerol stocks of plasmids were made and stored at - 80 °C for 
small scale protein expression test. 
2.13. Small Scale Protein Expression Test 
After the second transformation, target proteins can be expressed in EC.  An LB-agar plate was 
streaked by using a glycerol stock of cells and incubated in a TS Auto Flow CO2 water-jacketed 
incubator (USA) at 37 °C overnight. One colony was picked from grown colonies on the plate 
and was inoculated in to 2 mL of LB media. Then, optical density of cell culture was checked at 
600 nm by using Lambda 25 UV/ Vis Spectrometer (Perkin Elmer Instruments, USA). When 
optical density was between 1 and 1.2, cell culture was centrifuged at 3000 rpm, 25 °C for 5 min 
by using AvantiTM J-20 XP centrifuge (Beckman Coulter, USA). The supernatant was discarded, 
and a dilution was performed to get an optical density of 0.4. Cultures were grown for 20-30 min 
at 37 °C and 250 rpm in G24 environmental Incubator Shaker (New Brunswick Scientific Co. 
Inc, USA)   0.1 mL un-induced sample was put into 2.0 mL micro centrifuge tube for gel 
analysis. IPTG was added to a final concentration of 1 mM to express the protein.  A 0.1 mL 
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sample from 2 h, 4 h and overnight growth were analyzed by SDS-PAGE. Remaining cultures 
were harvested by AvantiTM J-20 XP centrifuge at 4300 rpm 4 °C for half an hour [19]. 
2.14. SDS-PAGE protocol 
Induced and un-induced samples were collected using an Eppendorf centrifuge 5415D 
(Brinkmann Instruments, USA) at 13200 rpm for 1 minute. After removal of the supernatant 
from the samples, sample buffer was added to the cell pellets and they were boiled in water bath 
for 5-10 min to lyse the cells and denature all proteins.  
PAGEr Precast gel (Cambrex, USA) was mounted into the Biorad Mini Trans-Blot cell (Biorad, 
USA) so the printed side faces the anode buffer chamber. Buffer chamber was filled with 
appropriate amounts of 1X electrode buffer. 10 µL of protein sample was loaded into each well. 
The electrophoresis apparatus was attached to Biorad Power Pac 300 (Biorad, USA) and voltage 
was adjusted to 125 V [23]. When the dye front nears the bottom of the gel, the run was 
complete. Then the gel was removed and stained in Coomassie Blue stain for half an hour by 
constantly rotating with RotoMix Type 50800 (USA). Finally, the gel was de-stained overnight 
and a picture was taken by using an Alpha Imager TM 2200 Multilmage TM Light Cabinet Alpha 
Innotech Corparation (Alpha Innotech Corporation, USA). 
2.15. Protein Purification in native conditions 
The cell pellet was thawed and the cells were re-suspended in lysis buffer; 1 mM 
Phenylmethylsulphonylfluoride (PMSF) and 1 mg/mL lysozyme at 10 mL per gram weight of 
protein. The cells were sonicated on ice with Virsonic 60 (The Virtis Company INS, USA).  Ten 
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10 s bursts at 0.6-0.7 W were used with a 10 second cooling period between each burst. The 
lysate was centrifuged at 10000 x g for 30 min at 4 °C in the AvantiTM J-20 XP centrifuge 
(Beckman Coulter, USA ) to pellet the cellular debris and supernatant containing the protein was 
saved. Purification was started by equilibrating of HiTrapTM 5 mL Chelating, HP column 
(Amersham Biosciences, USA) with 5 column volumes of lysis buffer (50 mM KH2PO4, 300 
mM NaCl, 10 mM imidazole, pH 8.0). The lysate was then applied to column and 5-10 column 
volumes of lysis buffer were used for washing the column. Second wash was made by adding 5-
10 column volumes of wash buffer (50 mM KH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0). 
Finally, protein was eluted with elution buffer (50 mM KH2PO4, 300 mM NaCl, 250 mM 
imidazole, pH 8.0).  
2.16. Protein Purification in denaturing conditions 
The cell pellet was thawed and the cells were re-suspended in 10 mL lysis buffer, or Buffer A 
per gram weight of protein. The cells were stirred for 60 min at room temperature. Lysate was 
centrifuged at 10,000 x g for 20-30 min at room temperature (RT) AvantiTM J-20 XP centrifuge 
(Beckman Coulter, USA) to pellet the cellular debris and the supernatant was saved. Purification 
was started by equilibrating a HiTrapTM 5 mL Chelating, HP column (Amersham Biosciences, 
USA) with 5 column volumes of Buffer A. Then lysate was applied to column and 5 column 
volumes of Buffer A were used for washing the column. Second wash was made by adding 5 
column volumes of wash buffer, or Buffer C. Finally, protein was eluted with 5 column volumes 
of elution buffers, buffer D and E.   
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2.17. Expression and purification of recombinant SaPLC 
E.coli BL21(DE3) placI cells harboring pET28b-SaPLC plasmid were grown at 37 °C in 6 liters 
of LB media containing 50 mg/mL kanamycin. When the OD600 of the culture reaches 0.8, IPTG 
was added to a final concentration of 1 mM and grown for 6 h. Cells were then pelleted and 
frozen at 80 °C. Prior to purification, the frozen cell pellet (13-14 g) was thawed in 80 mL lysis 
buffer supplemented with 1 Protease Inhibitor Cocktail Tablet (Roche,USA), lysozyme, DNAse 
and RNAse. The suspension was stirred for 1 hour and lysed by sonication on ice with Virsonic 
60 (The Virtis Company INS, USA).  Ten 30 s bursts at 0.6-0.7 W were used with a 2 min 
cooling period between each burst. This step was followed by centrifugation at 20,500 rpm for 1 
h. The column was first equilibriated with 5 column volumes of lysis buffer. Then, the 
supernatant was incubated with 10 mL of Ni-NTA Super flow resin (Qiagen, USA) for 1 h to 
ensure complete binding. The resin was poured into the column to let the protein flow and the 
flow through was added back to the column in order to maximize protein recovery. Then, the 
column was washed with 5 column volumes of wash buffer and protein was eluted with 3 
column volumes of elution buffer containing 250 mM imidazole. Three column volumes of 50 
mM ethylenediamminetetraacetate (EDTA) and 20 mM Tris-HCl, pH 8.5 were added to the 
column to get all proteins that were bound to the column. Fractions containing SaPLC was 
collected, concentrated by ultrafiltration and further purified by gel filtration column HiloadTM 
16-60 SuperdexTM 200 prep grade (Amersham Biosciences, USA)  in 0.5 mM EDTA, 20 mM 
Tris-HCl, pH 8.5 and 0.25 mM 1,4-dithiothreitol (DTT).  The fractions containing pure SaPLC 
were judged by SDS-PAGE, were combined and dialyzed in 2 L 10 mM HEPES (pH 8.0 ) for 8 
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h, then against 2 L of 1 mM HEPES (pH 8.0) overnight. Protein sample was concentrated 30 
mg/mL and was ready for crystallization trials.  
Another method used was 50 mM Tris-HCl, pH 8.0 and 20 mM NaCl for the gel filtration run 
and then loading the saPLC fraction to ion exchange column  (HiTrapTM 5 mL Q HP column) 
(Amersham Biosciences, USA) and elution with  a 20- 750 mM NaCl linear gradient. This 
protein sample was then concentrated to 35 mg/mL and used for crystal trials.  
2.18. Crystallization of recombinant saPLC 
SaPLC crystals were grown at 4 °C using the hanging drop vapor diffusion method in standard 
Linbro plates (Hampton Research, USA). Drops were set up using 1µL protein and 1µL mother 
liquor. The conditions were optimized using a grid array and varying concentrations of PEG 
17500, 1,4-dioxane and CaCl2.  
2.19. Molecular mechanics 3 (MM3) calculations by using Biomedcache 6.1 software 
The structures used for the calculations were from the PDB. 1OMO Alanine Dehydrogenase 
(AlaDH) from Archaeglobus fulgidus [5], 1X7D Ornithine Cyclodeaminase (OCD) from 
Pseudomonas putida [7], 1PJC Alanine Dehydrogenase (AlaDH) from Phormidium Lapideum 
[6] were used as frames for MM3 calculations. Water molecules were deleted to prevent their 
competition in interaction at the active site. 1PJC was used to introduce pyruvate (Substrate 4 for 
AlaDH mechanism) into 1OMO active site. For this purpose, program DSviewer was used to 
overlay 1PJC and 1OMO. The overlay was done by tethering the nicotinamide rings of the NAD 
cofactor in both structures and then 1PJC was deleted leaving the pyruvate bound to 1OMO. The 
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new file was saved and used for further calculations. The active site pockets of 1OMO and 1X7D 
were defined to include residues within 5 Å of the bound substrate and cofactor. Then, mutations 
were done to imitate active sites of the target proteins. The cofactor and the carboxyl carbon of 
the substrate were locked during the calculations. The substrate was changed in the structure and 
bond lengths were fixed by using the function of Biomedcache 6.1 [24]. To minimize the 
computational time and to ensure that the resultant energies were due to the active site substrate 
interactions, the enzyme’s residues were kept rigid except for the catalytic (active site) residues 
whose side chains were kept flexible. The complexed enzyme’s geometry was optimized using a 
MM3 force field in Biomedcache 6.1. The geometries were adjusted in a search of minimum 
potential energy, which involes the movement of the flexible atoms and the subsequent 
calculation of  the potential energy of the transient structure until the energy change between 
iterations was 0.001 kcal/mol [25]. 
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CHAPTER THREE: RESULTS AND DISCUSSION 
3.1. Results of medium scale project of cancer related proteins  
The bioinformatic data was gathered from various web-based programs and target proteins 
(which were the homologues of the unknown cancer proteins) were chosen for production in EC. 
General strategy can be summarized as follows:  
Human and mouse genomes in the Cancer Genome Anatomy project were browsed to find novel 
cancer proteins. Key words were mouse enzyme, human enzyme regulator, human biological 
process unknown, human molecular function unknown and human toxin [26]. Amino acid 
sequences of candidate cancer proteins were sent to the PDB [27] and if they had similarity to 
known proteins of more than 50 %, they were rejected because with the idea was to find novel  
structures. After that, the domains of them were searched by using SMART server [28] and 
proteins with transmembrane domains were removed from the candidates, because they were 
impossible to express, purify and crystallize in EC. Ninety human and 98 mouse cancer proteins 
were determined as targets and their bacterial homologues were searched by blast searches and 
fewer than 40% positives were rejected [29]. One hundred eighty two bacterial homologues were 
decided to be tested for this purpose. Some specific information such as amino acid content, 
estimation of pI, gravy and the estimated secondary structure of cancer proteins and homologues 
were gathered from EXPASY [30] and HNN [31]servers. All bioinformatics data for bacterial 
homologues and cancer proteins were summarized in Table 1,2 and 3 in Appendix B. 
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Genes of bacterial homologues were amplified using PCR. The following figures show the 
results of PCR. 1 Kb DNA ladder (in the first lane of the each image) was used for determining 
the size of the PCR products. The optimum conditions for each gene were given in the figure 
statements. 56 % of the genes (102/182) were successfully amplified. Mesophilic and 
thermophilic bacteria were given in the Table 2. Thermophilic genes appear easier to work with 
and gave better yields during PCR. 
Table 1. Types of Bacteria  
Bacteria  Type 
Thermoplasma  acidophilum DSM 1728 Thermophilic bacteria 
Staphylococcus aureus Mu50 Mesophilic bacteria 
Sulfolobus solfataricus P2 Thermophilic bacteria 
Escherichia coli K12-MG1655 Mesophilic bacteria 
Bacillus halodurans C-125  Mesophilic bacteria 
Streptococcus pneumoniae TIGR4 Mesophilic bacteria 
Thermotoga maritima MSB8 Thermophilic bacteria 
Nostoc sp. PCC 7120 Mesophilic bacteria 
Ralstonia solanacearum Mesophilic bacteria 
Thermoplasma  volcanium GSS1 Thermophilic bacteria 
Deinococcus radiodurans R1 Mesophilic bacteria 
Bacillus subtilis 168 Mesophilic bacteria 
Pseudomonas aeruginosa  PAO1 Mesophilic bacteria 
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 Figure 6. PCR set 1 
1. (8 mM MgCl2) TM1020, TM1020,TM0356,TM0443,TM1346,TM1823, SP1326, SP1326, 
SP1326  
2. (8 mM MgCl2) BH3683, BH1357, BH3629, gi 10174248, BH1070, BH1278  
3. (8 mM MgCl2) SS1652, SS0793, SS2547, SS0569, SS0337, SS1170, SS0685, SS0085, 
SS1452   
4. (8 mM MgCl2) SS2222, SS0223, SS0854, TA01411, SA1816, SA2627,  gi14020899, 
SA0781, SA2696, SA0253, SA2696, TA00156, TA00746, TA00751, TA00442, TA01295, 
TA00194. 
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Figure 7. PCR set 2 
5. (8 mM MgCl2) TM0416, TM1566, TM0537, TM1312, TM0043, TM0175, TM0022 
,TM0866, TM0927, TM1857, TM0314, TM1857, TM1719 ,TM0849, TM1020 
6. (8 mM MgCl2 and 2% DMSO) EC01435, EC01032, EC03302. EC03935, EC02481, 
EC03002, EC04135, EC02666, EC02469  
7. (8 mM MgCl2 and 2% DMSO) EC01568  
8. (8 mM MgCl2 and 0.5 M Betaine) NS4363 
9. (8 mM MgCl2 and 0.5 M Betaine) NS3025, NS0246, NS0100  
10. (8 mM MgCl2 and 0.5 M Betaine) NS2847, NS1896, NS5121. 
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Figure 8. PCR set 3 
11. (8 mM MgCl2 and 0.5 M Betaine) NS4815, NS0123, NS 4349, NS0123  
12  (8 mM MgCl2  and 2% DMSO for NS and  8 mM MgCl2 and 0.5 M Betaine for EC) NS1745, 
NSA0144, NS4068, NS3802, NS3690, NSB00157, NS1041, NS4349, NSD0012, EC00798, 
EC03789, EC02844  
13. (8 mM MgCl2 and 2% DMSO) EC00381, EC02570, EC02815, EC00986, EC00891, 
EC02894, EC03834, EC01442  
14. (8 mM MgCl2) TV0752, TV1361, TV1187, TV0081, TV0489, EC03608, EC03276, 
EC01746. 
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Figure 9. PCR set 4 
15. (8 mM MgCl2 and 2% DMSO for EC 8 mM MgCl2 for TM) EC02570, EC02815, EC00177, 
EC04060, EC00986, EC00891, EC02894, EC03834, EC01442, TM0416, TM1566, TM0738, 
TM0537, TM0043, TM1312, TM0175, TM0022 
16. (8 mM MgCl2 and 0.5 M Betaine) GI. 16080483, (8 mM MgCl2 and 1 M Betaine) GI. 
16080483, BS01704, (8 mM MgCl2 and 1.5 M Betaine)  
17.  (8 mM MgCl2 and 2% DMSO) EC01343, EC01791.  
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Twelve of the amplified genes (TM1020, TM0356, TM0184, TM1346, TM1346, EC02481, 
EC03002, EC04135, EC02666, EC02469, EC01568, SA2696, SA0253) were ligated into pQE-
30 UA vector that contains a six-histidine tag and transformed to Rosetta (DE3) placI cells. They 
were screened using the directional PCR procedure, statistically get positive inserts for the vector 
was 1/3. SA0253, EC03002, TM1020, SA2696 were positively verified that they were in the 
right orientation (Figure 10). They were expressed on a small scale, only TM1020 were produced 
an induced protein (Figure 11). Protein markers that were used included the combination of 
Bovine Serum Albumin (MW: 66000 da), β-amylase (MW: 55000 da), Carbonic Anhydrase 
(MW: 29000 da) and Lysozyme (MW: 14400 da).  
             
  Figure 10. Screening gel  
18. SA0253, EC03002  
19. TM1020, SA2696.  
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Figure 11.Small scale expression of TM1020  
Arrow shows the induced sample of TM1020. 
 
Due to the poor expression and the screening problem, the pQE-30 UA vector was not used in 
further experiments. The pET-28a vector was used instead. It had different restriction 
endonuclease cutting sites. Therefore, screening of inserts was easier and it has better expression. 
After adding restriction endonuclease cutting sites to the primers for genes, PCR was performed 
by using Pfu polymerase enzyme that has proofreading activity. The results were shown in 
Figure 12. Because of the difficulty in finding good bacterial homologues for cancer proteins, 
experiments were continued with 8 bacterial proteins that were very similar to unknown cancer 
proteins (EC01032, EC03276, TV1361, TV0311, SS2222, SS2223, TM0356, NS1896). 
Seven out of eight attempts were successfully cloned and ligated to pET-28a vector and screened 
by digestion of restriction endonucleases such as Nde I, Nhe I, Xho I and BamH I (Figure 13). 
The positively verified inserts were then transferred to the Rosetta (DE3) placI cell line.   
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Figure 12. PCR set 5 1. EC01032, TV1361, TV0311, SS2222  
2. TM0356, SS0223, EC03276.  
  
  
Figure 13.  Digestion screening   
EC01032 (Nde I and Xho I), TV1361(Nde I and BamH I) TV0311(Nde I and BamH I), 
EC03276(Nhe I and BamH I), TM0356 (Nde I and BamH I). 
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Five of these constructs were successfully expressed on a small scale (Figure 14) and three 
proteins (TV0311: Histidine ammonia lyase, EC01032: sarcosine oxidase-like protein and 
TV136: threonine dehydratase catabolic) were purified by using Ni-NTA resin (Figure 15). 
   
Figure 14. Small scale protein expression  
EC01032, TV1361, TV0311, EC03276, TM0356.  
    
Figure 15. Purification  
Purified TV0311, EC01032 and TV136.
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Statistical data for the proteins were given in Table 2 and 3 for genes that were amplified by T33 
polymerase enzyme and ligated into the pQE-UA 30 vector, genes that were amplified by Pfu 
polymerase enzyme and ligated to pET-28a vector, respectively. 
 
Table 2. Statistical data for first system (pQE-UA 30 vector) 
Yield of amplification  102 / 182 = % 56 
Yield of positive expression clones 4 / 12 = % 33 
Yield of protein expression  1 / 4 =  % 25 
Yield of protein purification  N/A (Never tried) 
 
Table 3. Statistical data for second system (pET-28a vector) 
Yield of amplification  7/ 8 = % 88 
Yield of positive expression clones 5/7  = % 71 
Yield of protein expression  4/5 =  % 80 
Yield of protein purification   3 / 4 = % 75 
 
 
In the following figures (Figures 16-21), the black circles show the region of target enzymes 
and their homologues that were produced and purified successfully. 
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Figure 16.  Relationship between percentage of extended strand and molecular weight of the 
proteins. 
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Figure 17. Relationship between percentage of alpha helices and molecular weight of the 
proteins. 
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Figure 18.Relationship between percentage of random coil and molecular weight of the proteins. 
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Figure 19. Relationship between molecular weight and gravy of the proteins. 
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Figure 20. Relationship between pI and molecular weight of the proteins. 
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Figure 21. Relationship between pI and gravy of the proteins. 
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3.2.  Results of  Structural Study of OCD  
3.2.1. Experimental results of OCD project 
OCD (ornithine cyclodeaminase) is a member of the mu-crsytallin protein family and it is an 
enzyme that catalyzes the conversion of ornithine to proline. OCD like 1 (EC 4.3.1.12) and OCD 
like 2 (EC 2.6.1.1)  proteins from Sulfolobus solfataricus were produced to show OCD activity. 
The first step was amplification of their genes by followed by the PCR using Pfu polymerase 
enzyme. Figure 22 indicated the 927 bp gene product of OCD like 1 and the 954 bp gene product 
of OCD like 2.  
 
 
Figure 22.  PCR reaction of OCD like 1 and OCD like 2.  
The pET28-a vector and inserts were prepared and inserts were ligated to the pET28-a vector 
followed by transformation of plasmid DNA into Nova Blue T1R competent cells. Then, colonies 
were screened for verification of inserts for OCD like 1 and 2 (Figure 23 and 24, respectively). 
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Figure 23. Screening results of OCD like 1 (All of them are positive). 
 
 
Figure 24. Screening results of OCD like 2.  
Positively verified inserts were transferred to Rosetta DE3 placI competent cells in order to 
express proteins. Expression results are summarized in Figure 25.   
 
 
Figure 25. Expression of OCD like 1 and OCD like 2. (Arrows show the expressed proteins) 
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Purification under native conditions (Figures 26 and 27) was attempted for OCD like 1 and 2, but 
no pure proteins were obtained, due to insoluble protein expression or buried His tag inside the 
protein. Therefore, another procedure of purification was used, referred to as purification under 
denaturing conditions (Figure 27 and 28). OCD like 1 was purified with very small yield and 
resulted in two separate pieces. Due to the degradation, the folded protein was not obtained, as 
shown in Figure 29.  
 
 
 
 
 
Figure 26. Purification of OCD like 1 under native conditions 
Lanes: 1. Protein marker 2. induced sample 3. lysate 4. flowthrough 5. wash fraction 1 6. wash 
fraction 2 7. elution fraction.   
 
 
Figure 27. Purification of OCD like 2 under native conditions 
Lanes: 1. Protein marker 2. induced sample 3. lysate 4. flowthrough 5. wash fraction 1 6. wash 
fraction 2 7. elution fraction.   
1   2     3    4     5    6    7      
1 2 3 4 5 6 7
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Figure 28. Purification of OCD like 1 under denaturing conditions 
Lanes: 1. Protein marker 2. induced sample 3.  wash fraction 2 4. elution fraction 1 5. elution 
fraction 2.  
 
 
Figure 29. Purification of OCD like 2 under denaturing conditions 
Lanes: 1. Protein marker 2. uninduced sample 3. induced sample 4. wash fraction 1 5. wash 
fraction 2  6. elution fraction  1  7. elution fraction 2. 
 
 
Figure 30. Folding of OCD like 1 Lanes: 1. elution fraction  1  2. folded sample. 
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3.2.2. Computational results of OCD project 
Homology modeling and frame methods can be used for drug design purposes. When the amino 
acid sequence of unknown protein are sent modeling servers such as Swiss Model Server, 3D 
structural models are created for the protein and this structure is used  in homology modeling. In 
the frame method, known 3D structures are used as frames and point mutations are made in their 
active site. The frame method approach was chosen in our calculations, because homology 
models are unlikely to be useful in modeling ligand docking (drug design) unless the sequence 
identity with the template is >70%, and even then, less reliable than an empirical crystallographic 
or NMR structure. Two known 3D structures of the mu-crystallin family were found for use as 
frame structures from the PDB:  1OMO Alanine Dehydrogenase (AlaDH) from Archaeglobus 
fulgidus and 1X7D Ornithine Cyclodeaminase (OCD) from Pseudomonas putida. OCD like 1 
from Sulfolobus solfataricus , human mu-crystallin and the sequences from 1OMO, 1X7D were 
aligned together and the active site amino acids 5 Å  from the substrate  and NAD and  the 
mutations that are necessary to imitate the active site of target enzymes were determined as 
shown in Appendix C. After making mutations on the frame files, MM3 calculations were started 
using the Biomedcache software. Frame energies of enzymes and binding energies of substrates 
on the enzyme active sites were calculated using the following formulas. In these equations, 
Gibbs the free energy of the complex correspond the energies of enzyme and substrate together. 
Following figures and Appendix C are summarized the results that were obtained. 
Frame Energy = ΔG enzyme with mutations - ΔG enzyme no mutations 
      ΔG binding energies = ΔG complex – (ΔG enzyme - ΔG substrate) 
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The relative binding energies for 1X7D, OCD like 1 mutant, and the human mu-crystallin mutant 
were found using the 5 substrates that are involved in the mechanism of OCD. OCD like 1 seems 
like to have OCD activity, but human mu- crystallin does not as we found in literature [32]. The 
third substrate gives an unfavorable ∆G for human mu-crystallin mutant  as shown in Figure 31.  
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Figure 31.  Testing of OCD activity on 1X7D frame.  
To understand OCD like 1 mutant behavior, fewer mutations were  made. Tyrosine 160, Aspartic 
acid 161, Threonine 162 and Tyrosine 163 were not changed and Figure 32 shows this new 
trend. It seems more reliable based on the protein of OCD 1 following the wild type enzyme. ∆G 
is unfavorable for the fourth substrate. In cell the fourth substrate can be converted to proline by 
proline dehydrogenase (pyrroline-5- carboxylate reductase). It may explain the low ∆G value 
[33]. 
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Figure 32.  Testing of OCD activity on 1X7D frame with less mutations.  
 
The active site of 1X7D is a very closed active site. Arginine 45, Lysine 69 and Arginine 112 
make contact with the carboxylate group of the substrate and Aspartate 228 helps the removal of 
the ammonia from the active site (COO- group acts as a nucleophile, this causes double bond 
formation and elimination of ammonia). There are no acidic amino acids near the substrate in the 
active site of human mu-crystallin and elimination of ammonia can not occur, so the substrate 
can be removed from this open active site easily. 
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1X7D wild type 1X7D mutant (Human μ-crystallin)
Substrate 3
Arg 45
Gln 140
Ala 139
Ala 203
Lys 232
Asp 228
Glu 56
Lys 69
Arg 112
Arg 112
Thr 71 Arg 229
Asn 166
Arg 162
Ala 203
Ile 78
Glu 140
Val 139
Val 225
Ornithine Cyclodeaminase activity 
 
Figure 33.  Comparison of the active sites of 1X7D wild type and human mutant. 
 
The 1OMO template appear to have OCD activity, opposite of the experimental data [5]. Binding 
energies for all substrates of mutants are unfavorable. Due to OMO not being a natural OCD like 
enzyme and the high frame energy of 1OMO, it is not a good frame for these calculations.  
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Figure 34.  Testing of OCD activity on 1OMO frame.  
 
When 1X7D frame and target proteins were checked for AladH activity (Figure 35), none of 
them show AlaDH activity. 1X7D and human mu-crystallin are tested for this activity 
experimentally, but researchers did not find any activity. Therefore, the calculations appear to fit 
the experimental data [7]. 
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Figure 35.  Testing of AladH activity on 1X7D frame.  
1OMO template and human mu-crystallin exhibited a similar trend in Figure 36, but this trend is 
not reasonable, because of lack of activity of human mu-crystallin. OCD like 1 shows totally 
different behavior. 
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Figure 36.  Testing of AladH activity on 1OMO frame.  
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3.3. Crystallization of SaPLC  
Phosphatidylinositol specific phospholipase C (PI-PLC) enzymes (EC. 3.1.4.11) are important 
enzymes involved in various cellular signaling cascades that originate from the binding of 
hormones, neurotransmitters and growth factors to specific extracellular receptors. Mammalian  
PI-PLCs are the most diverse class of enzymes and represent a complex organization of 
structural domains. The mammalian enzymes are known to use a Ca2+ cofactor in their active 
sites to accelerate the reaction, whereas the smaller and less complex bacterial enzymes utilize 
the guanidinium group of arginine. Due to the difficulties in investigating the larger mammalian 
enzymes, the bacterial PI-PLCs have become a model system for kinetic and structural 
investigations.  Therefore, Sa-PLC from Streptomyces antibioticus has been studied and 
crystallized to find its structure in order to understand the mechanism of action of mammalian  
PI-PLCs.  
SaPLC was expressed using the procedure in the experimental section and purified using affinity 
and gel filtration chromatographies (Figures 37 and 38) and crystallized with the conditions 
shown in Table 1 (Appendix D). Small and irregular shaped crystals have been obtained under 
these conditions. To grow larger crystals the purification method was changed. 50 mM Tris-HCl, 
pH 8.0 and 20 mM NaCl was used for gel filtration and ion exchange chromatography was added 
as an additional purification step, obtain purer protein and bigger SaPLC crystals. Table 2 in 
Appendix D shows the conditions of crystallization and very small crystals are obtained at the 
conditions that are shown in pink color. Conditions for making crystals needed to be optimized 
by trying Hampton Crystal screens such as Crystal screen 1 and 2; Grid screen NaCl, PEG/LiCl, 
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2-methyl-2,4-pentanediol, PEG 6000, Ammonium sulfate; PEG/ Ion screen, crystal screen cyro 
[34] and different concentrations of PEG and 1,4-dioxane. 
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Figure 37. Chromatogram of gel filtration run.  
 
Figure 38. Purification of SaPLC  Lanes: 1. Protein marker 2. lysate 3. flowthrough 4. wash  5. 
elution 1 6. elution 2 with EDTA 7. sample that is injected to gel filtration column 8.A8 9. B10 
10. B11 11. sample for crystal trays.  
A8 
B10 
B11 
1 2 3 4 5 6 7 8 9 10 11
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SaPLC was not pure enough to get crystals of sufficient size for data collection using X-ray 
diffraction, when 26 mg/mL filtered sample was used to set up the crystal trays. Similar trends 
were observed for all 3 trays, all of them were dry and small crystals are seen in heavy 
precipitates. 40 mg/mL filtered SaPLC is used for setting up crystal trays after the following 
purification run (Figures 39-41) and very tiny crystals were obtained as Figure 42 is shown.  
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Figure 39. Chromatogram of gel filtration run (50 mM Tris-HCl, pH 8.0 and 20 mM NaCl is 
used). 
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Figure 40. Chromatogram of ion exchange run (gradient elution). 
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Figure 41. Results of ion exchange run of SaPLC  
Lanes: 1. Protein marker 2. un-induced sample 3. induced sample 4. lysate wash  5. flowthrough 
6. wash 7. elution 8.sample that is injected to gel filtration column 9. B10 10. B9 11. B8 
12. sample for crystal trays.  
 
 
 
           
Figure 42. Crystals of SaPLC obtained using hanging drop technique A. Crystals in the drop B. 
Magnified version of crystals. 
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B
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4. CONCLUSION 
It is very hard to find similar or somewhat identical bacterial proteins with cancer proteins. pQE-
30 UA vector was not suitable for expression of bacterial homolog proteins of cancer proteins. 
pET-28 a vector can be used in future expression systems. Selection of targets, vectors and the 
expression strains of EC are very important to produce soluble protein. The following parameters 
are important to decide target proteins. Between these limits, target proteins can be produced and 
purified. 
Range of pI: 5-7.3 
Range of Hh%: 22-47% 
Range of Cc%: 33-49% 
Range of Ee%: 9-32% 
Range of Molecular weight: 28000-54000 
Range of gravy: -0.006 to -0.246 
OCD like 1 seems to have OCD activity, but the human enzyme does not, as described in the 
literature. None of them exhibits AlaDH activity. OCD like 1 could not be purified; therefore the 
determination of catalytic activity of it and the validation of frame method will require future 
studies. 
 
Adding chromatography steps increases the chance of getting purer proteins and bigger crystals. 
Small SaPLC crystals are obtained using hanging drop crystallization technique at the 
concentrations of % 24 PEG 17500, 1,4-dioxane for 40 mg/mL SaPLC protein. The conditions 
are currently optimizing to prepare well-diffracting crystals for X-ray diffraction studies.  
 56
APPENDIX A: CULTURE MEDIUM, BUFFERS AND EQUIPMENT 
SETTINGS 
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1. Culture Medium 
LB media components in 1 L  
Tryptone          10 g 
Yeast extract    5 g 
NaCl                 10 g 
 
2xTY media components in 1 L 
Tryptone          16 g 
Yeast extract    10 g 
NaCl                 5 g 
 
SOC media components in 1 L 
Tryptone   20g 
Yeast Extract   5g 
5M NaCl   2mL 
1M KCl   2.5mL 
1M MgCl2   10mL 
1M MgSO4   10mL 
1M glucose   20mL 
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2. SDS-PAGE buffers 
Electrode buffer (1X) 
25 mM Tris base 
192 mM Glycine 
0.1 %  SDS  
 
Sample buffer (1X) 
62.5 M Tris-HCl,  pH 6.8    
2 % SDS 
10 % Glycerol 
0.01 %  Bromophenol Blue  
2.5 %  2-mercaptoethanol 
 
Stain buffer 
0.1 %   Coomassie blue 
40 % Methanol 
10 % Acetic acid  
 
De-stain buffer 
25 % Isopropanol 
10 % Acetic acid  
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3. Purification buffers 
3.1. Buffers for purification under native conditions  
 
Lysis buffer (1L) 
50 mM KH2PO4 
300 mM NaCl 
10 mM imidazole 
Adjust pH 8.0 
 
Wash buffer (1L) 
50 mM KH2PO4 
300 mM NaCl 
20 mM imidazole 
Adjust pH 8.0 
 
Elution buffer  (1L) 
50 mM KH2PO4 
300 mM NaCl 
250 mM imidazole 
Adjust pH 8.0 
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3.1. Buffers for purification under denaturing conditions 
Buffer A : Lysis buffer (1L) 
100 mM KH2PO4 
10 mM Tris-HCl 
6 M GuHCl 
Adjust pH 8.0 
 
Buffer C: Wash buffer (1L) 
100 mM KH2PO4 
10 mM Tris-HCl 
8 M urea 
Adjust pH 6.3 
 
Buffer D: Elution buffer 1 (1L) 
100 mM KH2PO4 
10 mM Tris-HCl 
8 M urea 
Adjust pH 5.9 
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Buffer E: Elution buffer 2 (1L) 
100 mM KH2PO4 
10 mM Tris-HCl 
8 M urea 
Adjust pH 4.5 
 
4. Touch-down PCR cycle steps 
 
1. Denaturation at 92˚C for 45 s. 
2. Annealing at 65˚C for 1 minute.         
3. Decrease by 1˚C every cycle. 
4. Extension at 72˚C for 4 min. 
5. Cycle to step 1 for 25 more times. 
6. Denaturation at 92˚C for 45 s. 
7. Annealing at 55˚C for 1 minute. 
8. Extension at 72˚C for 4 min. 
9. Cycle to step 5 for 15 more times. 
10. Incubate at 72˚C for 15 min. 
11. Incubate at 4˚C forever. 
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5. Electroporation settings 
Cuvettes are kept at ice cold temperature prior to use. 
 
Cuvette size:   1 mm 
Choose mode:   T   2.5 kV/resistance high voltage (HV) 
Set capacitance:   C  Not  used in high voltage mode 
Set resistance:  R R5 (129 ohms) 
    BTX disposable cuvette P/N 610 (1 mm gap) 
Set charging voltage:  S 1.3-1.5 kV 
Desired field strength: 13.0-15.0 kV/cm 
Desired pulse length: t 5-6 msec 
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APPENDIX B: PROPERTIES OF CANCER RELATED PROTEINS AND 
HOMOLOGUES  
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Table 1. Homologues of Cancer Proteins  
Name of the proteins pI 
    (Hh)  
% 
    (Cc) 
% 
    (Ee) 
% MW 
# of  
AA 
 
GRAVY 
TA00156 myosin heavy chain (mhcA) related protein 5.19 60.83% 29.46% 9.71% 103436 896 -0.767 
TA00746 hypothetical protein 5.09 41.18% 36.27% 22.55% 23862.1 204 -0.198 
TA00751 conserved hypothetical protein  7.84 34.78% 42.03% 23.19% 7848 69 -0.465 
TA00442 hypothetical protein  4.27 32.00% 44.00% 24.00% 14489.6 125 -0.002 
TA01295 surface antigen genes (Methanosarcina mazei) related protein 3.97 11.62% 51.62% 36.76% 72253.1 680 0.137 
TA00194 death-associated protein kinase related protein 5.01 49.52% 39.42% 11.06% 23294.4 208 -0.274 
TA01411 methionyl aminopeptidase related protein  5.76 37.54% 44.37% 18.09% 32681.4 293 -0.255 
TA00957 xanthomonapepsin related protein  4.78 21.56% 49.91% 28.53% 119008 1090 0.149 
SA1816 truncated map-w protein  9.61 26.42% 47.17% 26.42% 12260.2 106 -0.497 
gi_14020899 hypothetical   protein  4.18 12.95% 61.61% 25.45% 26507.8 224 -0.86 
SA2574 immunodominant antigen A  6.35 53.80% 35.10% 11.10% 91410.5 829 0.165 
SA2627 hypothetical protein  9.03 78.99% 15.22% 5.80% 16390.1 138 1.288 
SA0781 hypothetical protein  4.8 39.53% 42.69% 17.79% 27261.7 253 -0.274 
SA2696 Drp35  6.24 34.92% 39.29% 25.79% 27529.6 252 -0.099 
SA0253 hypothetical protein  5.84 25.94% 46.97% 27.09% 38387.2 347 -0.07 
SS1652 Conserved hypothetical protein  6.64 67.07% 21.34% 11.59% 38737.7 328 -0.66 
SS0793 Ornithine carbamoyltransferase (argF)  6.02 44.30% 35.18% 20.52% 34439.9 307 0.016 
SS2547 Hypothetical protein  9.31 52.63% 30.14% 17.22% 24062.5 209 0.111 
SS0569 GTP-binding protein  9.37 50.60% 35.54% 13.86% 38193.5 332 -0.35 
SS0337 Heme biosynthesis related protein (nirJ-like) (nirJ-like) 8.68 47.83% 36.34% 15.84% 37350.8 322 -0.396 
SS1170 N-acetylglucosaminyltransferase related protein (nodC-like)  9.48 51.18% 31.99% 16.82% 48330.9 422 0.258 
SS0685 Spermidine synthase  5.67 47.51% 35.88% 16.61% 34853.9 301 -0.298 
SS0085 Conserved hypothetical protein  5.44 44.30% 35.09% 20.61% 25842.6 228 -0.22 
SS1452 Pyrrolidone-carboxylate peptidase, putative (pcp-like)  5.84 33.97% 48.33% 17.70% 23404.2 209 -0.09 
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Name of the proteins pI 
    (Hh)  
% 
    (Cc) 
% 
    (Ee) 
% MW 
# of  
AA 
 
GRAVY 
SS2222 RNA 3 terminal phosphate cyclase (RNA 3 phosphate 
cyclase) 9.34 42.03% 36.81% 21.16% 37841.2 345 -0.006 
SS0223 DNA repair protein radA (radA) 6.28 41.05% 38.27% 20.68% 35867 324 -0.237 
SS0854 Hypothetical protein  9.19 43.20% 43.20% 13.60% 13872.2 125 -0.202 
EC03608 heat shock protein 5.57 47.45% 40.15% 12.41% 15773.7 137 -0.525 
EC03276 orf, hypothetical protein 7.26 41.47% 44.41% 14.12% 38495.2 340 -0.246 
EC01746 orf, hypothetical protein  5.58 16.79% 62.77% 20.44% 15451.1 137 -0.738 
EC00381 orf, hypothetical protein  6.08 17.46% 58.73% 23.81% 7281.2 63 -1.275 
EC02570 prophage CP4-57 regulatory protein alpA  10.21 48.57% 47.14% 4.29% 8132.6 70 -0.331 
EC02815 putative proteoglycan  5.97 45.26% 40.09% 14.66% 51020 464 -0.119 
EC00177 orf, hypothetical protein  4.93 23.09% 53.70% 23.21% 90552.7 810 -0.483 
EC04060 enzyme in methyl-directed mismatch repair  6.31 42.76% 45.85% 11.38% 67923.7 615 -0.257 
EC00986 orf, hypothetical protein  5.1 48.17% 39.53% 12.30% 42218.9 382 -0.159 
EC00891 orf, hypothetical protein  8.7 52.93% 38.78% 8.29% 47655.8 410 -0.392 
EC02894 orf, hypothetical protein 4.86 54.24% 36.44% 9.32% 13979.8 118 -0.632 
EC03834 orf, hypothetical protein  4.69 74.07% 25.93% 0.00% 9634.8 81 -0.98 
EC01442 putative glycoportein 5.85 32.08% 44.03% 23.90% 36240.8 318 -0.294 
EC00229 probable peptide chain release factor  9.56 33.73% 47.59% 18.67% 18834 166 -0.755 
EC04199 orf, hypothetical protein 8.25 23.02% 55.45% 21.53% 43667 404 -0.275 
EC01435 orf, hypothetical protein  5.84 18.86% 55.22% 25.93% 32500 297 -0.132 
EC03302 putative hydrolase  5.25 48.29% 39.04% 12.67% 32915.4 292 -0.236 
EC02481 putative aminotransferase 6.04 43.45% 41.26% 15.29% 46061.6 412 -0.262 
EC03002 orf, hypothetical protein 9.17 38.69% 47.02% 14.29% 18673.3 168 -0.298 
EC04135 aspartate carbamoyltransferase, catalytic subunit  6.12 48.55% 36.98% 14.47% 34427.3 311 -0.105 
EC02666 pleiotrophic effects on 3 hydrogenase isozymes  5.35 48.28% 31.03% 20.69% 13168.1 116 -0.114 
EC02469 nucleoside diphosphate kinase  5.54 49.65% 39.86% 10.49% 15463.4 143 -0.082 
EC01568 orf, hypothetical protein 5.78 21.25% 58.97% 19.78% 29277 273 -0.207 
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Name of the proteins pI 
    (Hh)  
% 
    (Cc) 
% 
    (Ee) 
% MW 
# of  
AA 
 
GRAVY 
EC01792 orf, hypothetical protein 8.57 44.68% 42.55% 12.77% 5212.1 47 0.328 
EC03387 cell division membrane protein  4.47 46.68% 38.83% 14.49% 54513.3 497 -0.335 
EC01343 putative membrane protein  7.33 29.59% 55.79% 14.62% 114026 1122 -0.328 
gi_1790458 orf, hypothetical protein            5.82 37.50% 46.25% 16.25% 7386 80 0.44 
EC03713 arylsulfatase  5.93 26.50% 57.35% 16.15% 60717.6 551 -0.413 
EC02819 orf, hypothetical protein 5.86 37.36% 43.28% 19.36% 50244.2 439 -0.368 
EC03935 glycerol-3-phosphate acyltransferase  8.68 54.41% 35.31% 10.28% 93696.2 827 -0.157 
EC01442 putative glycoportein  5.85 32.08% 44.03% 23.90% 36240.8 318 -0.294 
EC00798 orf, hypothetical protein  5.91 47.23% 38.38% 14.39% 30412.8 271 -0.168 
EC03789 putative kinase  4.91 35.33% 45.00% 19.67% 31959.9 300 -0.057 
EC02844 proline aminopeptidase P II  5.25 36.73% 42.86% 20.41% 49815.4 441 -0.308 
EC01032 sarcosine oxidase-like protein  5.14 31.18% 48.66% 20.16% 40902 372 -0.234 
EC01791 cold shock protein 6.54 0.00% 56.52% 40.58% 7402.3 69 -0.19 
BH3683 potassium uptake protein  9.59 28.00% 49.71% 22.29% 39427.3 350 -0.307 
BH1357 ribosomal protein S21  11.45 52.63% 47.37% 0.00% 6844 57 11.45 
BH3629 flagellin synthesis regulatory protein (anti-sigma factor) 8.78 63.95% 36.05% 0.00% 10145.5 86 -1.226 
gi_10174248 spore cortex-lytic enzyme  5.57 40.61% 52.12% 7.27% 36564.9 330 -0.606 
BH1070 beta-xylosidase  5.66 41.24% 42.83% 15.94% 58432.5 502 -0.392 
BH1278 uridine kinase 5.48 46.92% 37.44% 15.64% 24387.2 211 -0.216 
BH2149 unknown conserved protein  4.29 59.78% 30.26% 9.96% 92222.9 823 -0.189 
BH2507 serine/threonine protein kinase  4.61 29.52% 51.51% 18.98% 73719.5 664 -0.426 
SP1326 neuraminidase, putative  8.07 14.19% 59.05% 26.76% 82437.4 740 -0.498 
gi_14972654 conserved domain   protein  5.36 31.75% 56.53% 11.72% 92229 819 -0.923 
 TM0416 D-tagatose 3-epimerase-related protein  5.74 47.41% 35.19% 17.41% 30464.1 270 -0.113 
TM1566 ribosomal protein S16  9.93 33.68% 45.26% 21.05% 11254.1 95 -0.698 
TM0537 hypothetical protein  5.39 69.26% 23.35% 7.39% 89185.6 758 -0.535 
TM0043 ABC transporter, ATP-binding protein  8.55 62.31% 23.24% 14.46% 66324.6 581 0.262 
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TM1312 conserved hypothetical protein  9.87 45.45% 41.56% 12.99% 8983.6 77 -0.36 
TM0175 acyl carrier protein  4.33 73.86% 26.14% 0.00% 10284.7 88 -0.305 
 TM0022 DNA mismatch repair protein  6.45 43.41% 35.66% 20.93% 59708.6 516 -0.318 
TM0866 conserved hypothetical protein  8.52 60.66% 23.28% 16.07% 34547.3 305 -0.104 
TM0898 hypothetical protein 5.56 50.00% 28.95% 21.05% 9222.7 76 -0.5 
TM0927 ferredoxin  4.15 3.33% 76.67% 20.00% 6213 60 -0.038 
TM0314 hypothetical protein 6.04 25.42% 64.41% 10.17% 6886.7 59 -1.137 
TM1857 conserved hypothetical protein  5.57 65.75% 22.83% 11.42% 58170.8 508 -0.568 
TM1719 DNA mismatch repair protein 5.77 47.54% 35.56% 16.90% 91065.9 793 -0.31 
TM0849 dnaJ protein  7.02 36.86% 49.86% 13.28% 42357.8 369 -0.805 
TM1020 hypothetical protein  5.33 45.89% 38.49% 15.62% 71171.8 608 -0.476 
TM0356 threonine dehydratase catabolic  6.08 46.38% 33.42% 20.20% 43110.1 401 0.145 
TM0184 phosphoglucomutase/phosphomannomutase family protein  5.38 40.56% 38.46% 20.98% 46948.7 429 -0.198 
TM1346 processing protease, putative 5.24 46.36% 36.17% 17.48% 47413.1 412 -0.358 
TM1823 ftsH protease activity modulator HflC  6.88 65.72% 18.73% 15.55% 32489.8 283 -0.068 
TM0738 hypothetical protein  8.89 53.42% 36.65% 9.94% 18091.9 161 -0.284 
TM0654 spermidine synthase 5.3 40.54% 35.81% 23.65% 34142 296 -0.287 
TM0443 gluconate kinase  5.56 35.50% 41.60% 22.90% 54153 476 -0.234 
NS0204 ATP-dependent DNA helicase  9.06 46.38% 38.02% 15.60% 82546 718 -0.424 
NS1927 unknown protein  5.12 51.03% 35.90% 13.08% 44673.1 390 -0.059 
NS1355 coproporphyrinogen III oxidase  5.7 31.41% 45.53% 23.05% 40030.5 347 -0.612 
NS0394 L-2,4-diaminobutyrate decarboxylase 5.01 50.37% 37.17% 12.45% 58500.5 538 0.027 
NS4245 probable N-acetyltransferase  5.37 55.49% 29.88% 14.63% 18580.2 164 -0.087 
NS3390 adenylosuccinate lyase  5.85 58.93% 33.41% 7.66% 48492.6 431 -0.068 
NS3992 serine/threonine kinase  6.03 30.85% 53.83% 15.32% 55276.7 496 -0.313 
NS5273 serine/threonine kinase  7.16 36.44% 52.13% 11.44% 42302 376 -0.551 
NS0539 1-pyrroline-5 carboxylate dehydrogenase  5.58 49.50% 35.04% 15.46% 110009 996 -0.176 
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NS1002 alanine--glyoxylate aminotransferase 5.78 49.08% 35.43% 15.49% 41869 381 -0.036 
NS2984 hypothetical protein 7.14 39.36% 50.00% 10.64% 31531.1 282 -0.185 
NS0695 probable 4-oxalocrotonate tautomerase 7.02 29.58% 47.89% 22.54% 8266.4 71 -0.566 
NS2161 gamma-glutamyl phosphate reductase  5.27 52.74% 31.96% 15.30% 47424.3 438 0.04 
NS4477 hypothetical protein  8.04 20.31% 46.88% 32.81% 7084.2 64 -0.072 
NS2748 hypothetical protein  6.09 43.22% 37.00% 19.78% 31175.8 273 -0.175 
NS3712 arginyl-tRNA-synthetase  5.3 52.89% 35.03% 12.07% 65814.9 588 -0.221 
NS3202 serine/threonine kinase  8.64 49.63% 38.95% 11.42% 61400.5 534 -0.178 
gi_17131946 ORF_ID:all2852~hypothetical  protein  5.69 39.62% 44.47% 15.90% 42551.4 371 -0.191 
NS1790 unknown protein  10.35 24.39% 41.46% 34.15% 9176.9 82 0.471 
NSA0198 plasmid recombinant protein  6.49 38.56% 46.65% 14.79% 64515.6 568 -0.592 
NS2634 unknown protein 10.53 0.00% 88.00% 12.00% 5729.5 50 -1.762 
NS4554 WD-40 repeat-protein 6.05 40.84% 38.30% 20.87% 88363.7 786 -0.218 
NS4363 serine/threonine kinase 8.27 23.28% 59.63% 17.09% 65147.9 597 -0.329 
NS2847 hypothetical protein  5.69 39.62% 44.47% 15.90% 42551.4 371 -0.191 
NS1896 RNA 3-terminal phosphate cyclase 8.89 42.53% 39.66% 17.82% 36637.3 348 0.161 
NS5121 hypothetical protein  5.56 45.64% 45.30% 9.06% 32214.2 287 -0.388 
NS3025 similar to Ras family protein  5.25 35.76% 37.58% 26.67% 18748.7 165 -0.084 
NS0246 WD-40 repeat protein 6.5 10.53% 47.04% 42.43% 32730.8 304 -0.17 
NS0100 unknown protein  4.68 34.88% 47.29% 17.83% 28776 258 -0.069 
NS1745 similar to WD-repeat containing protein  4.93 31.44% 40.51% 28.05% 38434.4 353 -0.088 
NSA0144 hypothetical protein 10.69 18.64% 59.32% 22.03% 6863.9 59 -0.729 
NS4068 unknown protein  9.52 53.72% 38.02% 8.26% 13509.4 121 -0.192 
NS3802 hypothetical protein 5.24 67.88% 26.82% 5.30% 70540.6 604 -0.513 
NS3690 N-acyl-D-glucosamine 2-epimerase  5.67 54.64% 37.63% 7.73% 45133.4 388 -0.39 
NSB0157 ORF_ID:asr7657~unknown protein  4.7 81.33% 18.67% 0.00% 8661.8 75 -0.396 
NS1041 hypothetical protein 4.68 30.08% 46.61% 23.31% 27588.1 236 -0.652 
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NS4815 hypothetical protein  5.37 59.24% 31.53% 9.24% 70589.4 628 0.018 
NS4349 cell death suppressor protein Lls1 homolog 7.61 30.47% 49.66% 19.86% 50792.5 443 -0.223 
NSD0012 ORF_ID:asr8513~unknown protein  9.55 27.27% 62.34% 10.39% 8001.3 77 0.018 
NS0123 leucine-rich-repeat protein  5.19 51.74% 34.94% 13.32% 126452 1119 -0.246 
RSA0571 hypothetical protein 9.68 41.46% 43.90% 14.63% 9673.8 82 -0.805 
RS2495 hypothetical hydrolase protein  6.7 31.87% 47.81% 20.31% 34463.3 320 -0.056 
RS2683 Conserved hypothetical protein   7.81 45.83% 40.83% 13.33% 25545.2 240 0.029 
RS2317 Conserved hypothetical protein   6.21 41.76% 39.01% 19.23% 19838.5 182 0.067 
RS0798 Putative purine nucleoside permease protein 8.82 35.17% 53.81% 11.02% 40581.9 381 -0.196 
RS0072 Probable Methionyl-TRNA formytransferase protein 6.06 32.11% 51.38% 16.51% 34237.3 327 0.047 
TV0752 Succinate dehydrogenase, hydrophobic anchor subunit 9.52 70.73% 24.39% 4.88% 13815.3 123 0.792 
TV1361 Histidine ammonia-lyase  5.42 55.56% 35.56% 8.89% 53955.9 495 -0.004 
TV1187 Transcription terminator (NusA related)  7.81 55.63% 21.13% 23.24% 16503.3 142 -0.154 
TV0311 RNase PH-related exoribonuclease  5.34 21.54% 46.54% 31.92% 28501.9 260 -0.074 
TV1407 Ankyrin repeat protein 5.64 47.62% 42.86% 9.52% 21312.3 189 -0.341 
TV0081 Uncharacterized conserved protein  7.7 82.71% 17.29% 0.00% 34853.7 295 -1.23 
TV0173 Uncharacterized conserved protein  6.02 5.80% 56.52% 37.68% 8040.9 69 -0.833 
TV0192 Aconitase A  5.92 30.87% 46.88% 22.25% 98339.4 881 -0.256 
TV1307 Aminopeptidase N 5.06 44.96% 38.70% 16.35% 88980.2 783 -0.292 
TV0230 ATPase involved in DNA repair  5.27 63.80% 27.04% 9.16% 103224 895 -0.649 
TV0489 30S ribosomal protein S24E  9.05 26.26% 46.46% 27.27% 11602.4 99 -0.811 
DR0938 hypothetical protein  9.08 16.71% 74.43% 8.86% 40003.1 395 -0.33 
DR0334 lipase, putative  7.67 27.37% 59.67% 12.96% 51755.4 486 -0.167 
DR1114 heat shock protein, HSP20 family 5.04 25.82% 64.84% 9.34% 20238.2 182 -0.829 
DRA0238 conserved hypothetical protein  9.2 38.60% 49.26% 12.13% 59405.3 544 -0.29 
DR0261 MutT/nudix family protein  5.04 30.21% 52.08% 17.71% 20366.2 192 0.001 
DR1130 protoporphyrinogen oxidase  5.78 36.58% 47.84% 15.58% 49622.7 462 -0.027 
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DR0058 serine/threonine protein kinase, putative  6.07 31.64% 50.08% 18.27% 64908.2 591 -0.206 
DR2518 serine/threonine protein kinase, putative  5.85 30.39% 51.50% 18.11% 71125.5 668 -0.09 
DR2535 hydrolase, putative 5.25 38.05% 47.81% 14.14% 33582.7 297 -0.426 
DR1487 enoyl-CoA hydratase 5.88 37.99% 49.72% 12.29% 75808.2 708 -0.293 
gi_16079145 yopK  5.92 52.59% 33.94% 13.47% 45320 386 -0.374 
gi_16080483 similar to spore coat   polysaccharide biosynthesis 5.85 47.09% 37.79% 15.12% 39809.3 344 -0.37 
gi_16079668 similar to phage-related  protein 5.04 50.00% 37.89% 12.11% 36247.6 322 -0.814 
BS01814 similar to endo-xylanase                
BS01704 mutS                
PA01586 2-oxoglutarate dehydrogenase (E1 subunit)  6.1 41.68% 43.37% 14.95% 105878 943 -0.378 
PA01157 ribonucleoside reductase, large chain 5.61 48.81% 40.08% 11.11% 107106 963 -0.309 
PA05064 ubiquinone biosynthesis methyltransferase UbiE  9.06 45.70% 41.41% 12.89% 28254.4 256 -0.248 
PA03314 probable ATP-binding component of ABC transporter  9.75 56.18% 34.46% 9.36% 28664.1 267 0.063 
PA04016 hypothetical protein 5.65 27.12% 63.73% 9.15% 62603.2 579 -0.55 
PA04476 conserved hypothetical protein 6.34 49.29% 35.82% 14.89% 30724 282 -0.147 
PA03247 hypothetical protein  5.65 36.36% 47.32% 16.32% 46658.5 429 -0.14 
PA02770 hypothetical protein 4.96 27.41% 50.97% 21.62% 28257.9 259 -0.142 
PA02292 hypothetical protein  9.48 40.86% 47.31% 11.83% 10732.3 93 -0.47 
PA03807 nucleoside diphosphate kinase  5.48 51.05% 37.06% 11.89% 15591.8 143 -0.089 
PA01580 hypothetical protein 7.71 35.64% 40.10% 24.26% 22110.4 202 -0.252 
PA00214 hypothetical protein 10.4 36.09% 49.57% 14.35% 25189.2 230 -0.178 
PA05481 hypothetical protein 9.49 14.06% 79.69% 6.25% 6792.5 64 -0.684 
gi_9948169 conserved hypothetical protein  5.77 40.21% 45.78% 14.01% 76329.5 664 -0.437 
PA05040 shikimate kinase  8.68 50.00% 31.98% 18.02% 19237.3 172 -0.259 
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ARS COMPONENT B PRECURSOR  5.21 28.16% 53.40% 18.45% 11185.9 103 0.202
SMAP-3  5.21 28.79% 53.54% 17.68% 22092 198 -0.708
ORAL-FACIAL-DIGITAL SYNDROME 1  5.82 60.57% 33.60% 5.83% 116671 1012 -0.808
adipose specific 2 5.17 84.21% 15.79% 0.00% 7854.7 76 -0.476
HGC6.2  protein  5.98 0.00% 77.19% 22.81% 6188.9 57 -0.421
aladin; adracalin  7.26 22.89% 56.78% 20.33% 59574.1 546 -0.084
DISRUPTED IN SCHIZOPHRENIA 1  5.91 47.54% 47.78% 4.68% 93598.5 854 -0.55
A GENE ISOLATED FROM A CPG ISLAND BETWEEN STS AND 
KAL  9.21 57.71% 32.81% 9.49% 27980.4 253 -0.008
THYROXINE DEIODINASE TYPE III [Hs] 6.31 41.73% 44.60% 13.67% 31281.7 278 -0.252
2'-5'OLIGOADENYLATE SYNTHETASE-LIKE 7.96 47.86% 36.58% 15.56% 59226 514 -0.362
ALPHA/BETA HYDROLASE DOMAIN CONTAINING PROTEIN 
2 6.24 36.24% 46.82% 16.94% 48314.8 425 -0.107
PROTEIN KINASE H11 5.00 1.53% 81.12% 17.35% 21604.3 196 -0.505
T54 PROTEIN  5.85 25.21% 61.76% 13.03% 52228.8 476 -0.686
SEC13 (S. CEREVISIAE)-LIKE 1 5.22 15.22% 53.42% 31.37% 35540.5 322 -0.372
FLAVIN CONTAINING MONOOXYGENASE 5  8.41 31.52% 46.53% 21.95% 60230.5 533 -0.222
HYA22 PROTEIN  8.95 29.41% 58.82% 11.76% 37875.4 340 -0.405
CER-D4 (MOUSE) HOMOLOG 7.65 33.93% 57.59% 8.48% 25825.3 224 -0.835
FETUIN B  6.87 22.77% 60.21% 17.02% 42094 382 -0.327
angiopoietin 4  9.10 49.90% 38.77% 11.33% 56848.5 503 -0.529
BARDET-BIEDL SYNDROME 2 PROTEIN 5.74 30.24% 46.88% 22.88% 79843.5 721 -0.152
Similar to cerebellar degeneration-related 2 5.12 60.05% 36.79% 3.16% 50549.7 443 -0.766
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PROLACTIN-INDUCED PROTEIN 8.26 33.56% 41.10% 25.34% 16572.4 146 0.175 
ATP-binding cassette, sub-family C, member 4; canalicular 
multispecific 8.93 51.43% 35.43% 13.14% 78564.3 700 0.079 
OSTEOGLYCIN PREPROPROTEIN 5.46 38.59% 46.98% 14.43% 33922.2 298 -0.268 
CGI-51 PROTEIN  6.85 30.70% 50.75% 18.55% 52160.4 469 -0.235 
SELENOPROTEIN X  8.64 7.76% 69.83% 22.41% 12610.1 116 -0.491 
SELENOPROTEIN W  9.30 52.87% 33.33% 13.79% 9297.9 87 -0.033 
FORMIN-LIKE 7.62 54.43% 39.74% 5.83% 52433.1 463 -0.458 
PM5 PROTEIN  5.61 17.02% 51.31% 31.67% 134348 1222 -0.154 
BREAST CANCER METASTASIS-SUPPRESSOR 1 4.69 52.85% 46.34% 0.81% 28460.6 246 -1.015 
HIN-1 4.49 31.03% 44.14% 24.83% 17036.1 145 -0.472 
mutS homolog 6  6.50 38.75% 48.16% 13.09% 152786 1360 -0.499 
mutS homolog 2 5.58 50.64% 36.51% 12.85% 104743 934 -0.24 
synuclein, gamma (breast cancer-specific protein 1) 4.97 40.94% 41.73% 17.32% 13300.8 127 -0.469 
deleted in liver cancer 1 7.92 33.36% 53.25% 13.38% 122817 1091 -0.605 
serologically defined colon cancer antigen 28 8.55 33.43% 52.37% 14.21% 40547.3 359 -0.528 
lung cancer candidate  9.69 31.82% 48.18% 20.00% 12073.7 110 -0.354 
deleted in bladder cancer chromosome region candidate 1 9.15 38.76% 44.94% 16.29% 88790.5 761 -0.475 
breast cancer antigen NY-BR-1  5.96 44.89% 49.07% 6.04% 152777 1341 -0.842 
highly expressed in cancer, rich in leucine heptad repeats  5.48 61.53% 32.87% 5.61% 73912.6 642 -0.749 
MAGE-C2  4.26 35.66% 53.35% 10.99% 41162.8 373 -0.224 
MAX interacting protein 1 6.72 35.16% 54.40% 10.44% 20557.8 182 -0.896 
mutL homolog 1 5.51 39.55% 44.58% 15.87% 84600.9 756 -0.353 
serologically defined colon cancer antigen 1  5.82 28.45% 60.50% 11.05% 41201.9 362 -1.295 
deleted in lung and esophageal cancer 1 isoform DLEC1-L1 8.65 33.76% 52.32% 13.92% 80353.5 711 -0.318 
downregulated in ovarian cancer 1  6.02 55.72% 37.77% 6.52% 87141.8 752 -0.959 
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serologically defined colon cancer antigen 33 8.35 34.93% 56.91% 8.15% 74845.6 687 -0.621 
postmeiotic segregation 1; human homolog of yeast mutL  6.23 33.26% 51.29% 15.45% 105830 932 -0.497 
alpha 1B-glycoprotein  5.56 16.77% 60.00% 23.23% 54253.5 495 -0.217 
prohibitin 5.57 52.21% 31.25% 16.54% 29804.1 272 0.024 
serologically defined colon cancer antigen 3  4.67 45.48% 50.28% 4.24% 39038.2 354 -0.579 
esophageal cancer associated protein  6.58 62.99% 28.28% 8.74% 94301.5 824 -0.069 
amphiphysin isoform 2  4.66 35.22% 54.06% 10.72% 71929.1 653 -0.636 
MEGAP TRANSCRIPT VARIANT A 6.23 43.31% 49.41% 7.28% 124504 1099 -0.633 
ACTIVE BREAKPOINT CLUSTER REGION-RELATED  PROTEIN 
ISOFORM B  5.92 41.61% 42.82% 15.57% 93577.6 822 -0.317 
HEAT SHOCK 27KDA PROTEIN 2; HEAT SHOCK 27KD PROTEIN 
2  5.07 20.33% 62.09% 17.58% 20232.5 182 -0.491 
CALPASTATIN  4.81 27.74% 70.61% 1.65% 71894.4 667 -1.169 
PROSAPOSIN  5.06 51.72% 39.69% 8.59% 58112.6 524 -0.064 
RENIN BINDING PROTEIN 5.86 51.80% 37.89% 10.31% 47746.6 417 -0.359 
CHIMERIN (CHIMAERIN) 2  7.04 40.81% 45.94% 13.25% 53923.5 468 -0.463 
REGULATOR OF G-PROTEIN SIGNALLING 14 8.46 36.22% 55.12% 8.66% 61446.9 566 -0.436 
FOLLISTATIN-LIKE 1 PRECURSOR 5.39 34.74% 50.65% 14.61% 34985.5 308 -0.617 
HT016  8.97 59.80% 30.15% 10.05% 23511.4 199 -0.554 
MAGO-NASHI HOMOLOG  5.74 33.56% 43.84% 22.60% 17163.6 146 -0.464 
NIEMANN-PICK DISEASE 7.57 13.25% 58.94% 27.81% 16570.2 151 -0.01 
MESOTHELIN ISOFORM 2 PRECURSOR 6.02 47.13% 48.57% 4.30% 69044.6 628 -0.132 
MAGE-LIKE PROTEIN 2 8.08 33.84% 57.09% 9.07% 58669.4 529 -0.458 
MAWD BINDING PROTEIN  6.55 37.65% 45.49% 16.86% 28151 255 -0.156 
downstream neighbor of SON isoform c 9.58 23.40% 65.66% 10.94% 29199.1 265 -0.561 
NEURONAL PENTRAXIN II  5.45 43.39% 47.10% 9.51% 47041.5 431 -0.247 
v-ski sarcoma viral oncogene homolog (avian) 7.73 40.66% 51.65% 7.69% 80005 728 -0.514 
t-complex-associated-testis-expressed 1-like 5.37 36.21% 44.83% 18.97% 13061.6 116 -0.129 
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SPASTIC ATAXIA OF CHARLEVOIX-SAGUENAY (SACSIN)  6.81 43.14% 42.86% 14.00% 436976 3829 -0.245 
SEPTIN 3 ISOFORM B; NEURONAL-SPECIFIC SEPTIN 3  6.35 37.39% 44.51% 18.10% 38741.4 337 -0.582 
CULLIN 4B 6.35 66.53% 27.62% 5.86% 84017.1 717 -0.442 
KERATOCAN 7.11 45.45% 44.32% 10.23% 40508.9 352 -0.217 
surfeit 2 9.33 21.88% 67.58% 10.55% 29617.5 256 -1.123 
PERIAXIN  5.65 27.89% 55.10% 17.01% 15931.2 147 -0.188 
SEPTIN 3 ISOFORM A 6.74 36.52% 45.80% 17.68% 39345.3 345 -0.497 
MEDITERRANEAN FEVER PROTEIN 8.30 31.11% 55.95% 12.93% 86443.7 781 -0.645 
PROLINE SYNTHETASE CO-TRANSCRIBED HOMOLOG 7.09 29.82% 49.45% 20.73% 30343.9 275 -0.3 
APOPTOSIS INHIBITOR  4.96 41.62% 39.31% 19.08% 20262.8 173 -0.549 
SEPTIN 3 ISOFORM C 9.99 20.00% 64.29% 15.71% 7702 70 -0.187 
immature colon carcinoma transcript 1 10.09 44.66% 44.66% 10.68% 23630.1 206 -0.778 
spermatogenesis associated PD1 9.00 33.65% 57.88% 8.46% 58427.3 520 -0.566 
SOC-2 SUPPRESSOR OF CLEAR HOMOLOG  8.65 48.28% 44.85% 6.87% 64854 582 -0.334 
GIGAXONIN 5.58 44.39% 41.04% 14.57% 67638.4 597 -0.235 
downstream neighbor of SON isoform b 9.54 22.81% 65.40% 11.79% 29068.9 263 -0.573 
perforin 1 (preforming protein) 8.04 33.87% 52.61% 13.51% 61393.3 555 -0.372 
tumor suppressor deleted in oral cancer-related 1  9.51 33.33% 66.67% 0.00% 13100.8 126 -0.421 
serologically defined colon cancer antigen 16 7.67 45.01% 47.73% 7.26% 87977.8 771 -0.941 
colon cancer-associated protein Mic1  8.10 41.40% 40.03% 18.57% 75043.7 657 -0.132 
AIM1 non-lens beta gamma-crystallin like protein 5.59 14.42% 65.79% 19.79% 179923 1637 -0.546 
Friedreich ataxia region gene X123 8.25 23.18% 63.67% 13.15% 32131.7 289 -0.451 
angiotensin II precursor 5.87 36.91% 46.19% 16.91% 53154.2 485 0.065 
choroideremia (Rab escort protein 1); REP-1 4.68 34.76% 48.24% 17.00% 73475.7 653 -0.355 
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protein kinase  5.96 36.39% 52.81% 10.80% 124321.3 1102 -0.437
coproporphyrinogen oxidase 7.18 33.33% 47.18% 19.49% 40648.1 354 -0.645
N-acetyltransferase 1  5.1 35.17% 41.38% 23.45% 33713.3 290 -0.251
histidine ammonia lyase 5.94 45.36% 40.33% 14.31% 72257.8 657 -0.103
PROLIFERATION-ASSOCIATED PROTEIN 1 6.41 43.15% 42.39% 14.47% 43698.8 394 -0.476
serine racemase  5.68 35.99% 43.66% 20.35% 36358.8 339 0.085
acid sphingomyelinase-like phosphodiesterase 3a 5.86 31.24% 46.74% 22.02% 49854.3 445 -0.143
RIKEN cDNA 2610002K22 5.07 23.02% 47.42% 29.55% 31665.3 291 -0.001
RIKEN cDNA 4930555L11 5.28 40.50% 43.53% 15.98% 41928.9 363 -0.224
Braf transforming gene 8.81 36.87% 49.17% 13.96% 73538.5 659 -0.366
otoconin-95 precursor  4.76 36.29% 55.05% 8.66% 52446.5 485 -0.2
glutamic acid decarboxylase 1 6.77 39.80% 46.88% 13.32% 66570 593 -0.323
N-acetyl transferase 3  6.07 32.76% 46.21% 21.03% 33685.6 290 -0.23
spermine synthase 4.9 33.61% 45.90% 20.49% 41313.2 366 -0.266
integrin linked kinase  8.3 36.95% 51.99% 11.06% 51347 452 -0.413
paraoxonase 1 5.07 30.14% 46.76% 23.10% 39531.1 355 0.001
neuraminidase 2 7.65 28.76% 55.15% 16.09% 42403.3 379 -0.282
RNA 3'-TERMINAL PHOSPHATE CYCLASE-LIKE 
PROTEIN  9.36 35.66% 45.31% 19.03% 40840.6 373 -0.01
RIKEN cDNA 2600013G09 5.05 44.09% 34.95% 20.97% 20813.8 186 0.001
RIKEN cDNA 2810411G20 9.18 40.76% 46.45% 12.80% 23934.2 211 -0.571
pyrroline-5-carboxylate synthetase 7.18 43.38% 38.59% 18.03% 87083 793 -0.095
Unknown (protein for MGC:19042) 6.36 37.63% 47.70% 14.66% 116448.9 1023 -0.347
glutamic acid decarboxylase 2 6.23 45.47% 40.51% 14.02% 65154.8 585 -0.184
peptidase 4  5.57 38.74% 43.61% 17.65% 55127.8 493 -0.144
SPERMIDINE SYNTHASE  5.31 38.74% 40.40% 20.86% 33994.9 302 -0.234
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Names of the protein pI 
  (Hh)  
%      (Cc) %
  (Ee) 
% MW 
# of 
AA 
 
GRAVY
lysyl oxidase 8.73 17.76% 71.53% 10.71% 46686.8 411 -0.793
proline dehydrogenase 6.35 51.71% 38.43% 9.86% 56773.7 497 -0.423
alanine-glyoxylate aminotransferase 8.57 41.65% 35.84% 22.52% 45815.1 413 -0.076
fructosamine 3 kinase  8.57 47.57% 41.42% 11.00% 35032 309 -0.368
arginyl-tRNA synthetase 7.49 55.45% 30.00% 14.55% 75721.5 660 -0.302
uridine-cytidine kinase 2  6.09 44.06% 42.15% 13.79% 29404.2 261 -0.4
Unknown (protein for IMAGE:4988981) 9.27 29.65% 55.84% 14.51% 35339.5 317 -0.432
acid beta glucosidase; glucocerebrosidase  7.64 29.71% 51.26% 19.03% 57621.8 515 -0.098
paraoxonase 2  5.31 28.81% 45.76% 25.42% 39491 354 -0.027
steroid sulfatase  8.83 33.81% 57.53% 8.65% 66590.8 624 -0.162
SNF1-like kinase 6.41 30.42% 58.92% 10.65% 85027.8 779 -0.242
legumain; protease 5.92 36.78% 44.83% 18.39% 49372.9 435 -0.368
neuraminidase 3 6.28 20.10% 58.13% 21.77% 46846.3 418 -0.279
group XII-1 phospholipase A2  6.85 42.71% 53.65% 3.65% 21289.3 192 -0.408
RIKEN cDNA 3110049J23  5.19 35.76% 46.88% 17.36% 31983.3 288 -0.231
insulin degrading enzyme 6.1 43.96% 43.47% 12.56% 117772.1 1019 -0.405
Unknown (protein for MGC:46960)  6.94 11.86% 74.96% 13.18% 66496.2 607 -0.73
hyaluronan synthase 2  8.85 51.63% 32.61% 15.76% 63492.2 552 0.159
paraoxonase 3 5.51 24.86% 48.59% 26.55% 39306.6 354 -0.022
adenylosuccinate lyase  6.9 58.26% 35.33% 6.40% 54808 484 -0.257
N-acetyltransferase 2 (arylamine N-acetyltransferase) 5.63 31.03% 45.17% 23.79% 33701.4 290 -0.334
folate hydrolase  7.08 36.84% 48.54% 14.63% 84635.2 752 -0.322
RIKEN cDNA 2810003H13  5.21 37.80% 41.63% 20.57% 22934.1 209 -0.082
RIKEN cDNA 2310020P08  9.47 29.02% 55.96% 29.02% 43095.2 386 -0.173
RIKEN CDNA 1700019D05  5.88 39.34% 49.76% 10.90% 23971.8 211 -0.148
hyaluronan synthase 3 8.94 62.27% 28.52% 9.21% 63338.8 554 0.201
protoporphyrinogen oxidase 9.07 36.06% 45.49% 18.45% 50870.5 477 0.004
budding uninhibited by benzimidazoles 1 homolog 5.31 40.78% 50.19% 9.03% 118403.4 1052 -0.536
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Names of the protein pI 
  (Hh)  
%      (Cc) %
  (Ee) 
% MW 
# of 
AA 
 
GRAVY
NIMA - related expressed kinase 2 8.91 48.98% 38.15% 12.87% 51307.9 443 -0.62
vanin 1; pantetheinase 5.57 33.40% 48.44% 18.16% 57031.2 512 0.031
thiopurine methyltransferase  6 46.25% 35.00% 18.75% 27585.6 240 -0.274
SERINE HYDROLASE PROTEIN  8.24 42.12% 43.09% 14.79% 35310.6 311 -0.212
small subunit DNA polymerase delta p12 6.06 29.91% 57.01% 13.08% 12403.1 107 -0.75
2-oxoglutarate dioxygenase 1 (gamma-butyrobetaine 
hydroxylase)  6.43 33.33% 45.48% 21.19% 44698.8 387 -0.38
unnamed protein product  4.71 26.46% 54.98% 18.56% 33095.3 291 -0.355
alpha-L-iduronidase  6.24 26.34% 55.21% 18.45% 71180.2 634 -0.149
puromycin-sensitive aminopeptidase  5.61 42.61% 41.63% 15.76% 103351.4 920 -0.212
ceroid-lipofuscinosis, neuronal 2  6.1 34.34% 53.38% 12.28% 61342.2 562 -0.19
neuraminidase 1 5.67 19.80% 57.95% 22.25% 44576.3 409 -0.198
NIMA-related expressed kinase 3 6.72 35.36% 53.05% 11.59% 57020.7 509 -0.564
aspartyl aminopeptidase 6.66 42.71% 42.71% 14.59% 52166.7 473 -0.142
group XIII secreted phospholipase A2  5.91 44.10% 45.13% 10.77% 21735.9 195 -0.211
RIKEN cDNA 2810411G20 5.91 43.26% 46.81% 9.93% 15772.9 141 -0.506
RIKEN cDNA 4733401N09 6.49 29.74% 54.58% 15.69% 33262.2 306 -0.033
iron response element binding protein  7.23 33.30% 48.48% 18.22% 98139.6 889 -0.156
ketohexokinase 5.81 35.91% 47.65% 16.44% 32750.3 298 -0.168
peroxisomal sarcosine oxidase  7.02 32.56% 50.00% 17.44% 43911.6 390 -0.177
carnitine palmitoyltransferase 2 8.46 41.34% 47.57% 11.09% 73927.4 658 -0.27
nitrogen fixation gene 8.69 40.31% 41.61% 18.08% 50717.2 459 -0.229
rhodopsin kinase; G-Protein receptor kinase 1 5.39 45.39% 43.97% 10.64% 63836.8 564 -0.39
PHOSPHOMANNOMUTASE 2  6.01 36.78% 42.15% 21.07% 27656.6 242 -0.457
L-specific multifunctional beta-oxdiation protein 9.16 30.99% 56.69% 12.32% 32050.7 284 -0.455
RIKEN cDNA 2600017H24 6.12 18.53% 60.14% 21.33% 63132.1 572 -0.535
expressed sequence C86324 5.22 47.70% 39.02% 13.28% 82910.7 738 -0.324
Bloom syndrome protein homolog (human)  6.9 31.00% 54.52% 14.48% 158365.8 1416 -0.596
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Names of the protein pI 
  (Hh)  
%      (Cc) %
  (Ee) 
% MW 
# of 
AA 
 
GRAVY
lecithin cholesterol acyltransferase 5.97 28.08% 55.25% 16.67% 49764.9 438 -0.252
phosphotriesterase related  6.18 41.26% 41.55% 17.19% 39218.1 349 -0.198
guanine deaminase  5.36 37.67% 46.04% 16.30% 51013 454 -0.183
nicotinamide N-methyltransferase 5.3 39.39% 47.35% 13.26% 29597.7 264 -0.244
vanin 3  5.94 28.82% 51.76% 19.41% 57489.4 5.94 -0.172
pyrroline-5-carboxylate synthetase 7.18 43.27% 38.62% 18.11% 87296.3 795 -0.094
similar to human ATP6C source AF363578.1  6.63 51.57% 33.77% 14.66% 43961.5 382 -0.311
phosphoacetylglucosamine mutase 5.8 40.77% 40.22% 19.00% 59452.6 542 -0.148
RIKEN cDNA 1110054A24  5.97 40.57% 46.93% 12.50% 51599.6 456 -0.193
choline/ethanolamine kinase  5.3 42.13% 48.98% 8.88% 45126.1 394 -0.437
nudix(nucleoside diphosphate linked moiety X)-type motif 1 5.3 39.74% 51.28% 8.97% 17908.3 156 -0.361
ribonucleotide reductase M1  6.27 44.32% 40.53% 15.15% 90220.2 792 -0.377
glyceronephosphate O-acyltransferase 8.39 58.41% 32.15% 9.44% 76869.6 678 0.064
N-terminal Asn amidase 5.78 27.74% 47.10% 25.16% 34595.3 310 -0.354
classical-complement pathway C3/C5 convertase  7.26 30.92% 52.89% 16.18% 84726.4 760 -0.295
N-acylsphingosine amidohydrolase 8.68 24.62% 49.75% 25.63% 44669.5 394 -0.212
RIKEN cDNA 2310009A18 8.06 32.51% 50.00% 17.49% 39226.3 366 -0.007
RIKEN cDNA 4432412E01 8.78 40.97% 47.28% 11.75% 38445.6 349 0.009
NME7  6.72 45.82% 43.80% 10.38% 44433.9 395 -0.256
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Table 1. Calculation results of OCD activity by using 1X7D frame 
Names of the files Electrostatics Hydrogen Bond   Van der Waals    
∆G  
(kcal/mol) 
1X7D OCD like mutant empty -635.374 -95.21 701.932 7423.3935
1X7D OCD like mutant substrate 1 -673.580 -201.859 796.857 7312.9788
1X7D OCD like mutant substrate 2 -725.397 -400.496 408.945 6602.8616
1X7D OCD like mutant substrate 3 -657.706 -253.828 763.376 7278.9774
1X7D OCD like mutant substrate 4 -623.612 -290.045 686.734 7203.2513
1X7D OCD like mutant substrate 5 -389.684 -294.465 713.557 7473.6036
1X7D human mu crystallin mutant empty 2.832 46.078 2468.584 10592.1208
1X7D human mu crystallin mutant substrate 1 -74.827 78.034 2447.697 10398.5079
1X7D human mu crystallin mutant substrate 2 -75.873 -12.476 2258.719 10088.1842
1X7D human mu crystallin mutant substrate 3 -117.461 32.917 2721.654 10755.1901
1X7D human mu crystallin mutant substrate 4 -66.295 36.183 2391.757 10155.2075
1X7D human mu crystallin mutant substrate 5 309.505 -11.226 2427.719 10741.1843
1X7D wild type enzyme empty -556.298 -396.232 180.046 5545.475
1X7D wild type substrate 1 -710.146 -573.507 202.31 5176.1339
1X7D wild type substrate 2 -559.865 -509.452 190.708 5220.0772
1X7D wild type substrate 3 -536.896 -531.482 206.166 5234.3666
1X7D wild type substrate 4 -402.608 -462.031 163.309 5375.3545
1X7D wild type substrate 5 -119.576 -537.331 180.085 5685.0115
Substrate 1  -21.42 -15.426 8.419 -23.7636
Substrate 2 -69.671 -14.389 8.369 -65.4515
Substrate 3 -46.108 -34.434 11.123 -68.7587
Substrate 4 -98.49 -1.211 3.523 -79.9509
Substrate 5 26.724 1.297 3.804 63.8589
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Table 2. Calculation results of alaDH activity by using 1X7D frame  
Names of the files Electrostatics Hydrogen Bond   Van der Waals   
∆G  
(kcal/mol) 
1X7D wild type enzyme empty -556.298 -396.232 180.046 5545.475
1X7D wild type substrate 1 -579.464 -508.222 178.167 5561.2081
1X7D wild type substrate 2 -849.277 -578.258 183.512 5232.0406
1X7D wild type substrate 3 -124.697 -471.622 165.494 5690.3780
1X7D wild type substrate 4 -562.819 -594.025 198.321 5520.4801
1X7D OCD like mutant substrate 1 -377.169 -235.174 720.771 7524.1494
1X7D OCD like mutant substrate 2 -561.018 -74.193 1429.921 8591.0654
1X7D OCD like mutant substrate 3 -443.267 -409.448 408.566 6891.8560
1X7D OCD like mutant substrate 4 -372.694 -236.581 685.660 7473.2606
1X7D human mu crystallin mutant substrate 1 330.410 21.836 2368.24 10789.1531
1X7D human mu crystallin mutant substrate 2 52.369 -60.942 2068.475 10052.4969
1X7D human mu crystallin mutant substrate 3 301.943 -57.771 1854.288 10037.0192
1X7D human mu crystallin mutant substrate 4 368.534 -28.705 2094.674 10424.0897
Substrate 1 31.724 -0.308 3.759 53.2026
Substrate 2 -76.038 -15.403 4.992 -76.3265
Substrate 3 35.14 -0.997 4.655 59.2206
Substrate 4 21.81 0 2.598 25.4137
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Table 3. Calculation results of OCD activity by using 1OMO frame   
Names of the files  Electrostatics Hydrogen Bond    Van der Waals   
∆G  
(kcal/mol) 
1OMO wild type enzyme empty -717.344 -314.695 169.68 7111.7046
1OMO wild type enzyme substrate 1 -1540.192 -505.407 259.714 6795.9769
1OMO wild type enzyme substrate 2 -1581.115 -531.603 266.842 6758.4606
1OMO wild type enzyme substrate 3 -1521.789 -492.575 246.547 6870.824
1OMO wild type enzyme substrate 4 -1440.442 -419.341 221.996 6982.7987
1OMO wild type enzyme substrate 5 -1257.24 -384.509 210.328 7215.3694
1OMO OCD like 1 mutant empty -184.956 -321.283 191.599 8181.3473
1OMO OCD like 1 mutant substrate 1 -267.925 -376.990 317.966    8144.9404 
1OMO OCD like 1 mutant substrate 2 -212.486 -246.498 346.949 8356.1533
1OMO OCD like 1 mutant substrate 3 -351.202 -516.321 266.146 7916.7369
1OMO OCD like 1 mutant substrate 4 -201.590 -442.738 216.591 8052.0437
1OMO OCD like 1 mutant substrate 5 124.139 -344.525 258.917 8513.6447
1OMO human mu crystallin mutant empty -1038.413 -160.538 226.479 8988.2513
1OMO human mu crystallin mutant substrate 1 -1152.677 -316.198 290.337 8692.5242
1OMO human mu crystallin mutant substrate 2 -1188.143 -340.782 301.712 8670.5558
1OMO human mu crystallin mutant substrate 3 -1087.378 -213.844 486.658 9479.1801
1OMO human mu crystallin mutant substrate 4 1039.378 -290.264 419.014 9109.3592
1OMO human mu crystallin mutant substrate 5 -769.748 -253.67 260.567 9138.7893
Substrate 1 -21.412 -15.433 8.4 -23.7572
Substrate 2 -69.337 -14.443 8.375 -65.3523
Substrate 3 -45.638 -34.677 11.304 -67.9532
Substrate 4 -98.449 -1.092 3.448 -80.1887
Substrate 5 24.183 0.98 3.988 61.667
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Table 4. Calculation results of alaDH activity by using 1OMO frame   
Names of the files  Electrostatics Hydrogen bond    Van der Waals 
∆G  
(kcal/mol) 
1OMO wild type enzyme empty -717.344 -314.695 169.68 7111.7046
1OMO wild type enzyme substrate 1 -1251.131 -403.895 216.248 7194.0403
1OMO wild type enzyme substrate 2 -1436.065 -497.432 242.39 6946.6587
1OMO wild type enzyme substrate 3 -1244.692 -413.479 219.703 7208.7512
1OMO wild type enzyme substrate 4 -1231.433 -402.182 214.519 7182.3126
1OMO OCD like 1 mutant empty -184.956 -321.283 191.599 8181.3473
1OMO OCD like 1 mutant substrate 1 122.492 -296.259 205.498 8482.2718
1OMO OCD like 1 mutant substrate 2 9.096 -182.615 352.954 8712.0096
1OMO OCD like 1 mutant substrate 3 135.254 -303.104 221.651 8536.1988
1OMO OCD like 1 mutant substrate 4 244.935 -194.556 329.006 8895.9478
1OMO human mu crystallin mutant empty -1038.413 -160.538 226.479 8988.2513
1OMO human mu crystallin mutant substrate 1 -788.169 -225.939 250.098 9171.4115
1OMO human mu crystallin mutant substrate 2 -1017.272 -336.032 281.057 8874.5486
1OMO human mu crystallin mutant substrate 3 -787.088 -234.389 248.625 9166.7401
1OMO human mu crystallin mutant substrate 4 -778.121 -253.148 267.283 9126.4001
Substrate 1 32.082 -0.647 3.712 52.7328
Substrate 2 -76.027 -15.402 4.987 -76.3265
Substrate 3 32.359 -1.152 4.464 55.9232
Substrate 4 21.806 0 2.609 25.4288
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                        10        20        30        40        50        60        70 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     ---METLILTQEEVESLISMDEAMNAVEEAFRLYALG-----KAQMPPKVYLEFEKGDLRAMPAHLMGYA 62 
  2 HuMu-Cryst  MSRVPAFLSAAEVEEHLRSSSLLIPPLETALANFSSGPEGGVMQPVRTVVPVTKHRGYLGVMPAYSAAED 70 
  3Consensus    ---METLILTQEEVESLISMDEAMNAVEEAFRLYALG-----KAQMPPKVYLEFEKGDLRAMPAHLMGYA 
 
                        80        90       100       110       120       130       140 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     GL--KWVNSHPGN-PDKGLPTVMALMILNSPETGFPLAVMDATYTTSLRTGAAGGIAAKYLARKNSSVFG 129 
  2 HuMu-Cryst  ALTTKLVTFYEDRGITSVVPSHQATVLLFEPSNGTLLAVMDGNVITAKRTAAVSAIATKFLKPPSSEVLC 140 
  3Consensus    GL--KWVNSHPGN-PDKGLPTVMALMILNSPETGFPLAVMDATYTTSLRTGAAGGIAAKYLARKNSSVFG 
 
                       150       160       170       180       190       200       210 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     FIGCGTQAYFQLEALRRVFDIGEVKAYDVREKAAKKFVSYCEDRGISASVQPAEEASRCDVLVTTTPSRK 199 
  2 HuMu-Cryst  ILGAGVQAYSHYEIFTEQFSFKEVRIWNRTKENAEKFADTVQG-EVRVCSSVQEAVAGADVIITVTLATE 209 
  3Consensus    FIGCGTQAYFQLEALRRVFDIGEVKAYDVREKAAKKFVSYCEDRGISASVQPAEEASRCDVLVTTTPSRK 
 
                       220       230       240       250       260       270       280 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     PVVKAEWVEEGTHINAIGADGPGKQELDVEILKKAKIVVDDLEQAKHGGEINVAVSKGVIGVEDVHATIG 269 
  2 HuMu-Cryst  PILFGEWVKPGAHINAVGASRPDWRELDDELMKEAVLYVDSQEAALK------ESGDVLLSGAEIFAELG 273 
  3Consensus    PVVKAEWVEEGTHINAIGADGPGKQELDVEILKKAKIVVDDLEQAKHGGEINVAVSKGVIGVEDVHATIG 
 
                       290       300       310       320       330       340       350 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     EVIAGLKDGRESDEEITIFDSTGLAIQDVAVAKVVYENALSKNVGSKIKFFRI 
  2 HuMu-Cryst  EVIKGVKP--AHCEKTTVFKSLGMAVEDTVAAKLIYDSWSSGK---------- 
  3Consensus    EVIAGLKDGRESDEEITIFDSTGLAIQDVAVAKVVYENALSKNVGSKIKFFR 
 
Figure 1.  Sequence alignment of 1OMO and Human mu-Crystallin  
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                        10        20        30        40        50        60        70 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     METLILTQEEVESLISMDEAMNAVEEAFRLYALGKAQMPPKVYLEFEKGDLRAMPAHLMGYAGLKWVNSH 70 
  2 SsOCD1      --MIILTRKDLDELLKAEIAVSSVKEAFKLHYQKKVDQPQRLVMSVKGNWWGLMPSSTDYSFVTKIVNVI 68 
  3Consensus    METLILTQEEVESLISMDEAMNAVEEAFRLYALGKAQMPPKVYLEFEKGDLRAMPAHLMGYAGLKWVNSH 
 
                        80        90       100       110       120       130       140 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     PGNPDKGLPTVMALMILNSPETGFPLAVMDATYTTSLRTGAAGGIAAKYLAR-KNSSVFGFIGCGTQAYF 139 
  2 SsOCD1      PENKERGLPLVQGVVILMSPDTGEILAIIDGTTLTAIRTAAASILSTELAINGRNIGILGIIGAGTEAYY 138 
  3Consensus    PGNPDKGLPTVMALMILNSPETGFPLAVMDATYTTSLRTGAAGGIAAKYLAR-KNSSVFGFIGCGTQAYF 
 
                       150       160       170       180       190       200       210 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     QLEALRRVFDIGEVKAYDVREKAAKKFVSYCEDRGISASVQPAEEASRCDVLVTTTPSRKPVVKAEWVEE 209 
  2 SsOCD1      HAKLALEYFKVQKLYIS------ARKSHFELAKRVGGEATDLETLLKNSDTIFATTSSNFPVVLGKYLKD 202 
  3Consensus    QLEALRRVFDIGEVKAYDVREKAAKKFVSYCEDRGISASVQPAEEASRCDVLVTTTPSRKPVVKAEWVEE 
 
                       220       230       240       250       260       270       280 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     GTHINAIGADGPGKQELDVEILKKAK-IVVDDLEQA-KHGGEINVAVSKGVIGVEDVHATIGEVIAGLKD 277 
  2 SsOCD1      VFHLSSIGAHTPDSRELDDDTIIKVKSYIVDSLEAVSKESGDYIIPKQRGLLENKMIKELGEIIEKGIKI 272 
  3Consensus    GTHINAIGADGPGKQELDVEILKKAK-IVVDDLEQA-KHGGEINVAVSKGVIGVEDVHATIGEVIAGLKD 
 
                       290       300       310       320       330       340       350 
                         |         |         |         |         |         |         | 
  1 AfAlaDH     GRESDEEITIFDSTGLAIQDVAVAKVVYENALSKNVGSKIKFFRI                   
  2 SsOCD1      ERPS-----LFKTVGIAVEDNITAHIAYQEALRRGIGFNVSI---                   
  3Consensus    GRESDEEITIFDSTGLAIQDVAVAKVVYENALSKNVGSKIKFFR 
 
Figure 2.  Sequence alignment of 1OMO and OCD like 1  
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                        10        20        30        40        50        60        70 
                         |         |         |         |         |         |         | 
  1 PpOCD       MTYFIDVPTXSDLVHDIGVAPFIGELAAALRDDFKRWQAFDKSARVASHSEVGVIELXPVADKSRYAFKY 70 
  2 SsOCD1      ----MIILTRKDLDELLKAEIAVSSVKEAFKLHYQ--KKVDQPQRLVMSVKGNWWGLMPSSTDYSFVTKI 64 
  3Consensus    MTYFIDVPTXSDLVHDIGVAPFIGELAAALRDDFKRWQAFDKSARVASHSEVGVIELXPVADKSRYAFKY 
 
                        80        90       100       110       120       130       140 
                         |         |         |         |         |         |         | 
  1 PpOCD       VNGHPANTARNLHTVXAFGVLADVDSGYPVLLSELTIATALRTAATSLX-AAQALARPNARKXALIGNGA 139 
  2 SsOCD1      VNVIPENKERGLPLVQGVVILMSPDTGEILAIIDGTTLTAIRTAAASILSTELAINGRNIGILGIIGAGT 134 
  3Consensus    VNGHPANTARNLHTVXAFGVLADVDSGYPVLLSELTIATALRTAATSLX-AAQALARPNARKXALIGNGA 
 
                       150       160       170       180       190       200       210 
                         |         |         |         |         |         |         | 
  1 PpOCD       QSEFQALAFHKHLGIEEIVAYDTDPLATAKLIANLKEYSGLTIRRASSVAEAVKGVDIITTVTADKAYAT 209 
  2 SsOCD1      EAYY-----HAKLALEYFKVQKLYISARKSHFELAKRVGG----EATDLETLLKNSDTIFATTSSN--FP 193 
  3Consensus    QSEFQALAFHKHLGIEEIVAYDTDPLATAKLIANLKEYSGLTIRRASSVAEAVKGVDIITTVTADKAYAT 
 
                       220       230       240       250       260       270       280 
                         |         |         |         |         |         |         | 
  1 PpOCD       IITPDXLEPGXHLNAVGGDCPGKTELHADVLRNAR-VFVEYEPQTRIEGEIQQLPADFPVVD--LWRVLR 276 
  2 SsOCD1      VVLGKYLKDVFHLSSIGAHTPDSRELDDDTIIKVKSYIVDSLEAVSKESGDYIIPKQRGLLENKMIKELG 263 
  3Consensus    IITPDXLEPGXHLNAVGGDCPGKTELHADVLRNAR-VFVEYEPQTRIEGEIQQLPADFPVVD--LWRVLR 
 
                       290       300       310       320       330       340       350 
                         |         |         |         |         |         |         | 
  1 PpOCD       GETEGRQSDSQVTVFDSVGFALEDYTVLRYVLQQAEKRGXGTKIDLVPWVEDDPKDLFSHTRGRAGKRRI 346 
  2 SsOCD1      EIIEKGIKIERPSLFKTVGIAVEDNITAHIAYQEALRRGIGFNVSI------------------------ 309 
  3Consensus    GETEGRQSDSQVTVFDSVGFALEDYTVLRYVLQQAEKRGXGTKIDLVPWVEDDPKDLFSHTRGRAGKRRI 
 
Figure 3.  Sequence alignment of 1X7D and OCD like 1  
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                        10        20        30        40        50        60        70 
                         |         |         |         |         |         |         | 
  1 PpOCD       MTYFIDVPTXSDLVHDIGVAPFIGELAAALRDDFKR------WQAFDKSARVASHS-EVGVIELXPVADK 63 
  2 HuMu-Cryst  MSRVPAFLSAAEVEEHLRSSSLLIPPLETALANFSSGPEGGVMQPVRTVVPVTKHRGYLGVMPAYSAAED 70 
  3Consensus    MTYFIDVPTXSDLVHDIGVAPFIGELAAALRDDFKR------WQAFDKSARVASHS-EVGVIELXPVADK 
 
                        80        90       100       110       120       130       140 
                         |         |         |         |         |         |         | 
  1 PpOCD       SRYAFKYVNGHPANTARNLHTVXAFGVLADVDSGYPVLLSELTIATALRTAATSLXAAQALARPNARKXA 133 
  2 HuMu-Cryst  ALTTKLVTFYEDRGITSVVPSHQATVLLFEPSNGTLLAVMDGNVITAKRTAAVSAIATKFLKPPSSEVLC 140 
  3Consensus    SRYAFKYVNGHPANTARNLHTVXAFGVLADVDSGYPVLLSELTIATALRTAATSLXAAQALARPNARKXA 
 
                       150       160       170       180       190       200       210 
                         |         |         |         |         |         |         | 
  1 PpOCD       LIGNGAQSEFQALAFHKHLGIEEIVAYDTDPLATAKLIANLKEYSGLTIRRASSVAEAVKGVDIITTVTA 203 
  2 HuMu-Cryst  ILGAGVQAYSHYEIFTEQFSFKEVRIWNRTKENAEKFADTVQG----EVRVCSSVQEAVAGADVIITVT- 205 
  3Consensus    LIGNGAQSEFQALAFHKHLGIEEIVAYDTDPLATAKLIANLKEYSGLTIRRASSVAEAVKGVDIITTVTA 
 
                       220       230       240       250       260       270       280 
                         |         |         |         |         |         |         | 
  1 PpOCD       DKAYATIITPDXLEPGXHLNAVGGDCPGKTELHADVLRNARVFVEYEPQTRIEGEIQQLPADFPVVDLWR 273 
  2 HuMu-Cryst  -LATEPILFGEWVKPGAHINAVGASRPDWRELDDELMKEAVLYVDSQEAALKESGDVLLSGAEIFAELGE 274 
  3Consensus    DKAYATIITPDXLEPGXHLNAVGGDCPGKTELHADVLRNARVFVEYEPQTRIEGEIQQLPADFPVVDLWR 
 
                       290       300       310       320       330       340       350 
                         |         |         |         |         |         |         | 
  1 PpOCD       VLRGETEGRQSDSQVTVFDSVGFALEDYTVLRYVLQQAEKRGXGTKIDLVPWVEDDPKDLFSHTRGRAGK 343 
  2 HuMu-Cryst  VIKGVKP--AHCEKTTVFKSLGMAVEDTVAAKLIYDSWSSGK---------------------------- 314 
  3Consensus    VLRGETEGRQSDSQVTVFDSVGFALEDYTVLRYVLQQAEKRGXGTKIDLVPWVEDDPKDLFSHTRGRAGK 
 
                       360       370       380       390       400       410       420 
                         |         |         |         |         |         |         | 
  1 PpOCD       RRIRRVA                           
  2 HuMu-Cryst  -------                           
  3Consensus    RRIRRV 
 
Figure 4.  Sequence alignment of 1X7D and Human mu Crystallin  
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APPENDIX D: CRYSTAL GROWTH CONDITIONS OF SaPLC 
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Table 1. Crystal conditions with CaCl2 
 
Tray 1 
26 % PEG 
2.25 %1,4-
dioxane 
5 mM CaCl2 
26 % PEG 
2.25 %1,4-
dioxane 
7 mM CaCl2 
26 % PEG 
2.25 %1,4-dioxane 
7.5 mM CaCl2 
26 % PEG 
2.25 %1,4-
dioxane 
8 mM CaCl2 
26 % PEG 
2.25 %1,4-
dioxane 
9 mM CaCl2 
26 % PEG 
2.25 %1,4-
dioxane 
10 mM CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
5 mM CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
7 mM CaCl2 
27 % PEG 
2.25 %1,4-dioxane 
7.5 mM CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
8 mM CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
9 mM CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
10 mM CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
5 mM CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
7 mM CaCl2 
28 % PEG 
2.25 %1,4-dioxane 
7.5 mM CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
8 mM CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
9 mM CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
10 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
5 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
7 mM CaCl2 
29 % PEG 
2.25 %1,4-dioxane 
7.5 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
8 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
9 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
10 mM CaCl2 
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Tray 2 
25 % PEG 
1.5  %1,4-
dioxane 
7.5 mM 
CaCl2 
26 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
27 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
28 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
30 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
25 % PEG 
1,75 %1,4-
dioxane 
7.5 mM 
CaCl2 
26 % PEG 
1.75  %1,4-
dioxane 
7.5 mM 
CaCl2 
27 % PEG 
1.75 %1,4-
dioxane 
7.5 mM 
CaCl2 
28 % PEG 
1.75 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
7.5 mM 
CaCl2 
30 % PEG 
1.75 %1,4-
dioxane 
7.5 mM 
CaCl2 
25 % PEG 
2.25 %1,4-
dioxane 
7.5 mM 
CaCl2 
26 % PEG 
2.25 %1,4-
dioxane 
7.5  mM 
CaCl2 
27 % PEG 
2.25 %1,4-
dioxane 
7.5 mM 
CaCl2 
28 % PEG 
2.25 %1,4-
dioxane 
7.5  mM 
CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
7.5  mM 
CaCl2 
30 % PEG 
2.25 %1,4-
dioxane 
7.5  mM 
CaCl2 
25 % PEG 
2.5 %1,4-
dioxane 
7.5  mM 
CaCl2 
26 % PEG 
2.5 %1,4-
dioxane 
7.5  mM 
CaCl2 
27 % PEG 
2.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
28 % PEG 
2.5 %1,4-
dioxane 
87.5 mM 
CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
7.5  mM 
CaCl2 
30 % PEG 
2.5 %1,4-
dioxane 
7.5  mM 
CaCl2 
 
 
 91
Tray 3 
29 % PEG 
1.5 %1,4-
dioxane 
5 mM CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
7 mM CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
8 mM CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
9 mM CaCl2 
29 % PEG 
1.5 %1,4-
dioxane 
10 mM CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
5 mM CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
7 mM CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
8 mM CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
9 mM CaCl2 
29 % PEG 
1.75 %1,4-
dioxane 
10 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
5 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
7 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
8 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
9 mM CaCl2 
29 % PEG 
2.25 %1,4-
dioxane 
10 mM CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
5 mM CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
7 mM CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
7.5 mM 
CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
8 mM CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
9 mM CaCl2 
29 % PEG 
2.5 %1,4-
dioxane 
10 mM CaCl2 
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Table 2. Crystal conditions  
Tray 1 
20 % PEG 
1.5 %1,4-
dioxane 
 
21 % PEG 
1.5 %1,4-
dioxane 
 
22 % PEG 
1.5 %1,4-
dioxane 
 
23 % PEG 
1.5 %1,4-
dioxane 
 
24 % PEG 
1.5 %1,4-
dioxane 
 
25 % PEG 
1.5 %1,4-
dioxane 
 
20 % PEG 
1.75 %1,4-
dioxane 
 
21 % PEG 
1.75 %1,4-
dioxane 
 
22 % PEG 
1.75 %1,4-
dioxane 
 
23 % PEG 
1.75 %1,4-
dioxane 
 
24 % PEG 
1.75 %1,4-
dioxane 
 
25 % PEG 
1.75 %1,4-
dioxane 
 
20 % PEG 
2 %1,4-
dioxane 
 
21 % PEG 
2 %1,4-
dioxane 
 
22 % PEG 
2 %1,4-
dioxane 
 
23 % PEG 
2 %1,4-
dioxane 
 
24 % PEG 
2 %1,4-
dioxane 
 
25 % PEG 
2 %1,4-
dioxane 
 
20 % PEG 
2.25 %1,4-
dioxane 
 
21 % PEG 
2.25 %1,4-
dioxane 
 
22 % PEG 
2.25 %1,4-
dioxane 
 
23 % PEG 
2.25 %1,4-
dioxane 
 
24 % PEG 
2.25 %1,4-
dioxane 
 
25 % PEG 
2.25 %1,4-
dioxane 
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Tray 2 
25 % PEG 
1.5  %1,4-
dioxane 
26 % PEG 
1.5 %1,4-
dioxane 
 
27 % PEG 
1.5 %1,4-
dioxane 
 
28 % PEG 
1.5 %1,4-
dioxane 
 
29 % PEG 
1.5 %1,4-
dioxane 
 
30 % PEG 
1.5 %1,4-
dioxane 
 
25 % PEG 
1,75 %1,4-
dioxane 
 
26 % PEG 
1.75  %1,4-
dioxane 
 
27 % PEG 
1.75 %1,4-
dioxane 
 
28 % PEG 
1.75 %1,4-
dioxane 
 
29 % PEG 
1.75 %1,4-
dioxane 
 
30 % PEG 
1.75 %1,4-
dioxane 
 
25 % PEG 
2  %1,4-
dioxane 
 
26 % PEG 
2  %1,4-
dioxane 
 
27 % PEG 
2  %1,4-
dioxane 
 
28 % PEG 
2  %1,4-
dioxane 
 
29 % PEG 
2  %1,4-
dioxane 
 
30 % PEG 
2  %1,4-
dioxane 
 
25 % PEG 
2.25 %1,4-
dioxane 
 
26 % PEG 
2.25 %1,4-
dioxane 
 
27 % PEG 
2.25 %1,4-
dioxane 
 
28 % PEG 
2.25 %1,4-
dioxane 
 
29 % PEG 
2.25 %1,4-
dioxane 
 
30 % PEG 
2.25 %1,4-
dioxane 
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